


06/04/26
CURRICULUM VITAE

Shyamasundaran Kottlil, MD, PhD, FIDSA, MACP
Professor, Department of Medicine
Chief, Division of Infectious Diseases
Director, Division of Clinical Care and Research
Interim Director, Institute of Human Virology
University of Maryland School of Medicine

Date: June 04, 2026

Contact Information

Business Address: 725 W Lombard Street
Room N562
Baltimore, MD 21201

Business Phone: 410-706-4872

Fax : 410-706-2499

E-mail: skottlil@ihv.umaryland.edu
Shyamasundaran.kottlil@nih.gov

Foreign languages: Malayalam (Proficient); Hindi (Fluent); Tamil (Fluent); Sanskrit (Fluent)

Education

1991 MBBS, Medical College, Trichur, Kerala, India
1993 - 1997 Ph.D. in Immunology (Faculty of Medicine) from Memorial University of
Newfoundland, St. John's, NF

Postgraduate Education and Training

1991 - 1993 Postgraduate Training, Medical College, Calicut, Kerala, India
1997 - 2000 Internal Medicine Residency Program at Brown University School of
Medicine, USA
2000 - 2003 Infectious Diseases Fellowship with Dr. Anthony S. Fauci at National
Institute of Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, MD

Certifications:

2000 - 2010	ABIM Board Certified in Internal Medicine
2002 - 2012	ABIM Board Certified in Infectious Diseases
2010 - 2020	ABIM Board re-certified in Internal Medicine
2012 - 2022	ABIM Board re-certified in Infectious Diseases
2020 - 2030	ABIM Board re-certified in Internal Medicine
2022 – 2032	ABIM Board re-certified in Infectious Diseases

Medical Licensures

2001 - present	Commonwealth of Virginia Board of Medicine, Active
2009 - present	District of Columbia, Department of Health Board of Medicine, Active
2014 - present	State of Maryland Department of Health and Mental Hygiene/ Maryland Board of Physicians, Active
206-present	State of Florida Department of Health of Board of Medicine, Active

Employment History

Academic Appointments

2003 - 2014	<i>Faculty</i> , Washington D.C. Community Outreach PACT Program
2005 - 2014	<i>Faculty</i> , NIH International Society of Infectious Diseases HIV Training Program
2014 - 2018	Associate Director, Division of Clinical Care and Research, Institute of Human Virology, Baltimore, MD
2010 - present	<i>Visiting Professor</i> , Institute of Liver and Biliary Sciences, New Delhi, India
2010 - present	<i>Faculty</i> , Liver Immunology Laboratory, Institute of Liver and Biliary Sciences, New Delhi, India
2014 - present	Special volunteer, Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD
2014 - present	<i>Professor</i> , Medicine, University of Maryland School of Medicine, Institute of Human Virology, Baltimore, MD
2015 - present	Consultant Scientist, Global Virus Network (GVN), Baltimore MD
2014 - 2018	Director, Clinical Trials Unit, Institute of Human Virology, Baltimore, MD
2018 - present	Director, Division of Clinical Care and Research, Institute of Human Virology, Baltimore, MD
2018 - present	Director, Clinical Research, Institute of Human Virology, Baltimore MD
2018 - present	Chief, Division of Infectious Diseases, University of Maryland, Baltimore, MD
2023-present	<i>Interim Director</i> , Institute of Human Virology, University of Maryland School for Medicine

Other Employment

2003 - 2014	<i>Staff Clinician</i> , Immunopathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
-------------	--

July 2009 - present	<i>Scientific Director, NIH-District of Columbia Program for AIDS Progress</i>
Sept 2014 - present	<i>Senior Scientific Advisor, Global Virus Network (GVN)</i>
Jan 2019 - present	<i>Advisor, Government of Uzbekistan Hepatitis Elimination Project</i>
May 2019 - present	<i>Advisor, Louisiana Hepatitis C Elimination project</i>
Jan 2019 - present	<i>Scientific Advisor, Govt of Kerala, India Institute of Advanced Virology</i>
Dec 2019 - present	<i>Member, Governing Board, John C Martin Centre for Liver Research and Innovations, Kolkata, India</i>
May 2019 - present	<i>Member, Scientific Advisory Board. John C Martin Centre for Liver Research and Innovations, Kolkata, India</i>
June 2019 - present	<i>Member, Director Search Committee, Institute of Advanced Virology, Trivandrum, India</i>
2024- present	<i>Adhoc Reviewer, King Abdullah International Medical Research Center (KAIRMRC), Riyadh, Saudi Arabia</i>
2025-present	<i>Adhoc Reviewer, King Abdul Aziz University, Jeddah, Saudi Arabia</i>
2025-present	<i>Reviewer Member, Board of Scientific Council, National Heart Lung Blood Institute (NHLBI), NIH, Bethesda, MD</i>

Professional Society Memberships

1996 - present	<i>Member, International AIDS Society (IAS)</i>
1997 - present	<i>Member, American College of Physicians (ACP)</i>
1999 - 2010	<i>Member, American Society of Microbiology (ASM)</i>
2000 - 2014	<i>Member, Greater Washington Infectious Diseases Society (GWIDS)</i>
2008 - present	<i>Member, American Association for the Study of Liver (AASLD)</i>
2009 – 2015	<i>Member, International Society for Interferon and Cytokine Research (ISICR)</i>
2012 - present	<i>Member, Infectious Diseases Society of America (IDSA)</i>
2012 - present	<i>Member, European Association of the study of Liver (EASL)</i>
2015 - present	<i>Member, Asia-Pacific Association of the Study of the Liver (APASL)</i>
2017 - present	<i>Member, American Society of Clinical Investigation (ASCI)</i>
2019- present	<i>Member, American Association for Advancement of Science (AAAS)</i>

Honors and Awards

1993	<i>Awarded Memorial University of Newfoundland Fellowship to pursue graduate studies</i>
1994	<i>Obtained the Memorial University of Newfoundland Immunology Graduate Program prize.</i>
1995	<i>Obtained ECFMG certificate.</i>
1996 - 1997	<i>Co. Investigator National Human Resources Development Program (NHRDP)</i>
1997	<i>Canadian Society of Immunology Scholarship</i>
1998	<i>Obtained USMLE Step 3 licensing exam in December 1998.</i>
2005	<i>Clinical Curriculum Certificate with Commendation</i>
2005	<i>NIH Bench to Bedside award recipient</i>

2006	NIH Bench to Bedside award recipient
2007	NIH Bench to Bedside award recipient
2007	NIAID DIR Supplemental award recipient
2009	NIAID DIR Supplemental award recipient
2009	Office of AIDS Research (OAR) cycle 2 award recipient
2009	Office of AIDS Research (OAR) cycle 3 award recipient
2010	Office of AIDS Research (OAR) cycle 1 award recipient
2010	Distinguished Mentor award nominee
2010	NIAID DIR Supplemental award recipient
2011	NIH Bench to Bedside award recipient
2011	Office of AIDS Research Award (OAR) cycle 1 award recipient
2012	NIH Bench to Bedside award recipient
2012	Fellow, American College of Physicians
2014	NIAID Outstanding Mentor Award recipient
2014	NIAID Merit AWARD for Innovations in Science
2015	Clinical Publication of the Year Award (Univ of MD School of Medicine)
2015	Fellow of the Infectious Diseases Society of America (FIDSA)
2016	Clinical research Forum Top Ten Manuscript (Osinusi et al JAMA 2015)
2016	Fellow at The American Society of Clinical Investigation (ASCI)
2017	Full tenure at the University of Maryland School of Medicine
2018	Chairman's Special Achievement Faculty Award
2019	ACP Richard and Hinda Rosenthal Award Recipient (to that physician-scientist, clinician, or scientific group whose recent innovative work is making a notable contribution to improve clinical care in the field of internal medicine)
2019	Chairman's Special Achievement Faculty Award
2020-present	COVID-19 Human Subjects Research Coordinating committee
2020-present	COVID-19 Research Advisory Task
2020-present	COVID-19 Clinical Research Advisory Task force
2020-present	COVID-19 Clinical Research Study Section
2021	Chairman's Special Achievement Faculty Award
2021	Elected as Master of American College of Physicians (MACP)
2021	Elected as Fellow of the Royal College of Physicians (Lon)
2021	Elected as Fellow of the American Association of the Study of Liver Diseases (FAASLD)
2022	Chairman's Special Achievement Faculty Award
2023	Lifetime Achievement Award from Kerala Center, New York
2023	Chairman's Special Achievement Faculty Award
2024	Elected as Fellow of the National Academy of Medical Sciences, India
2024	Chairman's Special Achievement Faculty Award
2025	Received John C Martin Endowment for Distinguished Chair at IHV (\$5 Million)
2025	Chairman's Special Achievement Faculty Award

Clinical Program Development

2014 -2018 *Director, Clinical Trials Unit, Institute of Human Virology*

Clinical/Administrative Service

Institutional Service

2014 - 2018 *Associate Chief, Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine*

2014 - present *Faculty, University of Maryland School of Medicine Infectious Diseases Fellowship Program*

2014 - present *Faculty, Division of Infectious Diseases, UMD Midtown Campus, Baltimore*

2015 - present *Faculty, University of Maryland Medical Schools Admissions Interview Committee*

2015 - present *Attending Physician, University of Maryland School of Medicine, Division of Infectious Diseases*

2015 - present *Attending Physician, University of Maryland Midtown Campus, Division of Infectious Diseases*

2015 - present *Faculty, University of Maryland Graduate School (Microbiology and Immunology)*

2015 - present *Advisory Committee Member, University of Maryland School of Medicine Medical Scientist Training Program (MSTP)*

2015 - present *Faculty, University of Maryland Graduate School (Epidemiology and Public Health)*

2015 - present *Faculty Search Committee Member, Institute of Human Virology and University of Maryland School of Medicine*

2015 - present *Faculty, Summer Bioscience Internship Program at University of Maryland*

2015 - present *Member, University of Maryland Medical School Admissions Interview Committee*

2015 - present *Member, University of Maryland School of Medicine Internal Medicine Residency Program Interview Committee*

2015 - present *Member, University of Maryland School of Medicine Infectious Diseases Fellowship Interview Committee*

Local and National Service

Local Service

1999 - 2000 *House Staff Committee, Brown University School of Medicine*

2015 -2017 *Mentoring Committee, American College of Physicians, DC Chapter*

2018 - present *Member, NIAID ACTG Transformative Strategic Group (Hepatitis-TSG)*

National Service

2000 - 2002 *Member, NIAID Fellowship Advisory Committee, NIH*

2000 - 2003 *Member, NIH Fellows Committee (FELCOM)*

2001 - 2003 *Co-chair*, NIH Distinguished Clinical Teacher Sub committee
 2001 - 2003 *Member*, NIH Medical Executive Committee
 2005 - 2007 *Grant Reviewer*, Wellcome Trust, London, United Kingdom
 2006 *The Journal of Infectious Diseases-Editorial Advisory Board*
 2006 *Guest Editor*, Hepatology International: Hepatitis Research and Treatment (Special Issue).
 2007 - 2008 *Member*, NIH Barriers to Clinical Research Committee
 2007 - 2013 *Member*, NIAID Institutional Review Board
 2009 - 2016 *Co-chair*, NIH-District of Columbia HIV-Hepatitis Consortium
 2009 - 2014 *Member*, Advisory Committee on NIH policy for FDA regulated Research
 2009 - present *Scientific Director*, NIH-District of Columbia Program for AIDS Progress
 2009 - 2014 *Volunteer ID Physician*, Free hepatitis and HIV clinic at Whitman Walker clinic, N.W. Washington DC
 2010 *Organizer*, First NIH-ILBS Symposium on HIV-HCV and Comorbidities, New Delhi, India
 2010 - 2011 *Acting Chair*, NIAID Institutional Review Board
 2010 - 2013 *Member*, Medical Advisory Board for NIH-DC Program for AIDS Progress,
 2011 *Organizer*, Tissue Banking Workshop, New Delhi, India
 2012 - 2014 *Volunteer ID Physician*, Free hepatitis, and HIV clinic at Family and Medical Counseling Services, Anacostia S.E. Washington DC
 2012 - present *Grant Reviewer*, Canadian Institutes of Health Research (CIHR)
 2012 - present *Core Faculty*, International Antiviral Society (IAS), USA
 2012 - present *Grant reviewer*, DC-Center for AIDS Research (DC-CFAR)
 2013 - 2013 *Chair*, HCV Symposium Conference on Retroviruses and Opportunistic Infections
 2013 - 2017 *Expert Panel Member*, IDSA-AASLD Joint Panel on HCV treatment Recommendations
 2014 - 2014 *Chair*, HCV Therapy, The Liver Meeting
 2015 - present *Member*, National Viral Hepatitis Working Group on Development of Treatment Guidelines for Hepatitis for the Government of Rwanda
 2015 - present *Organizing Committee Member*, 17th Annual IHV Meeting, Baltimore MD
 2015 - 2016 *Co-Chair*, Organizing Committee for IHV-GWU Joint Workshop in HIV infection
 2015 - present *Mentor*, Mentoring Committee for Infectious Diseases Fellows, ID Week
 2015 - present *Mentor*, D Chapter ACP Mentor Program
 2018 - present *Speaker*, ACP DC Chapter
 2017 - present *Member*, Study Monitoring committee NIAID ACTG A5360
 2018 - present *Member*, Study Monitoring committee NIAID ACTG A5370
 2021 - present *Founding Member*, ASCI Diversity, Equity, and Inclusion Committee
 2021 - present *Editor*, Frontiers in Immunology
 2021 - present *Editor*, AIDS Reviews
 2023 - present *Member*, Study Monitoring committee NIAID ACTG A5394

NIH Study sections (past two years)

2024	NIAID IICT review panel
2024	CDMRP PRMRP DIS-ID-01 panel
2024	Chair, CIHR HIVAIDS STBBI panel
2025	NIAID IICT review panel
2025	Chair, CIHR HIVAIDS STBBI panel
2025	PCORI 24C3 Dissemination and Implementation panel
2025	NIAID ZAI1-LP-Z (M1)-1 panel
2025	NIAID ZAI1 VSR-X (M3)
2025	NIAID R61/R33 Special Emphasis panel
2025	CDMRP PRMP DIS-ID01 panel

International Service

2012 - present	<i>Visiting professor</i> , Institute of Liver and Biliary Sciences, New Delhi, India
2015 - present	<i>Visiting faculty</i> , Indian Institute of Liver and Digestive Sciences, Kolkata, India
2015 - present	<i>Member</i> , National Viral Hepatitis Working Group on Development of Treatment Guidelines for Hepatitis for the Government of Rwanda

Teaching Service

2002 - 2014	Attending Physician/Staff Clinician Outpatient Clinic and Laboratory Summer Research Training Program, National Institutes of Health 35 undergraduates, 8 hours/day for 3 months/year
2003 - present	Attending Physician/Staff Clinician Outpatient Clinic and Inpatient Service University of Maryland Institute of Human Virology and National Institutes of Health 17 Residents/Fellows, 8 hours/day, 2-8 weeks/year
2014 - present	Attending Physician/Staff Clinician Outpatient Clinic and Laboratory University of Maryland Institute of Human Virology and National Institutes of Health 6 Medical Students; 1 hour/quarterly for 12 months
2014 - present	Attending Physician/Staff Clinician Outpatient Clinic and Laboratory University of Maryland, Institute of Human Virology and National Institutes of Health 13 post-Graduates, 1 hour/month, 12 months

2014 - present Attending Physician
 Clinical Research Trials Unit
 University of Maryland, Institute of Human Virology
 12 Assistant Professors, 4 hours/month, 12 months

2017 - 18 Mentor
 PREV 710 Course
 Clinical and Translational Research project Design and
 Implementation

2018 - present Speaker
 PREV 701 Course
 Cancer epidemiology

Active NIH Grants

09/24/2021-09/23/2026 Principal Investigator, 5%; MPI: Kottilil, University of Maryland
 G. Mani Subramanian ((Mitopower Inc)
 Novel therapy for alcoholic liver disease-associated hepatorenal
 syndrome
 NIH/NIAAA 1U44AA029833-01
 Total Costs: \$6,850,000
 Role MPI

05/01/2023-04/30/2026 Co-investigator 1% (PI: Stephen Davis MD)
 JHU Institute for Clinical and Translational Medicine
 Role: co-investigator (CTSA)
 1UL1TR003098-01

09/29/2023 - 09/28/2029 Co- Investigator; PI: Elana Rosenthal, University of Maryland
 NIH Contract for District of Columbia Program for AIDS Progress
 NIH Office of AIDS Research/CCMD/CC/NIH
 HHS, Contract (RTOP)
 Total Direct Costs: \$9,807,675

01/12/2022-01/11/2027 ACTG Subaward
 NIH/NIAID Subaward: 15600000027560
 Advancing Clinical Therapeutics Globally for HIV/AIDS and Other
 Infections [ACTG LOC: Chair A5423]
 Total Direct \$3875
 Role: ACTG Chair Hepatitis Transformative Group

12/01/2020 – 11/30/2027 Co-investigator, 5%; PI: Amita Gupta & Charles Flexnor, Johns
 Hopkins University Baltimore – India Clinical Trials Unit

The proposed Clinical Trials Unit will join the most active HIV clinical research sites in Baltimore, Pune, and Chennai, India, to optimize patient-oriented research and to access key populations affected by this epidemic for participation in clinical trials. (JHUBI-CTU).

NIH/NIAID, UM1 AI069465

Total Direct Costs: \$50,017

Role: Co-investigator, Site PI

03/01/22-02/28/27

Coinvestigator (PI: Manhattan Charurat)

Fogarty/NIH

INSIGHT (Integrated Network of Scholars in Global Health Research Training) program to strengthen research capacity at Low- and Middle-income Country (LMIC) institutions.

TBA

Coinvestigator: (PI: Poonam Mathur DO, MPH)

CD38 intensifies immune activation in women living with HIV

NIH/NIDA 1R21HD115013

Total Direct Costs: \$275,000

Role: Coinvestigator

TBA

PI: (Shyam Kottlil MD, PH.D)

Institute of Human Virology Annual Meeting

NIH/NIAID R13AI046078

Total Direct Costs: \$387,950

Role: PI

TBA

MPI: (Shyam Kottlil MD, PH.D/Alip Ghosh PhD)

Contribution of NAD⁺ depletion in effector T cell on inflammaging among people with HIV

NIH/NIA 1R01AG090155

Total Direct Costs: \$2,493,863

Score: 37

Role: MPI

Grants awaiting NOA

TBA

MPI: (Shyam Kottlil MD, PH.D/Alip Ghosh PhD)

Impact of opioid use disorder on mitochondrial dysfunction among antiretroviral therapy-receiving aging people with HIV

NIH/NIDA 1R01DA065079

Total Direct Costs: \$2,453,573

Role: MPI

Grants under review

MPI (Kottlil/Su)
NIDDK/NIH-RO-1
IFN-I and Pathogenic Macrophages in HIV/ART-associated liver diseases in PLWH
Total Direct Cost: \$2,359,608
Review pending

MPI Mathur/Kottlil
NIA/NIH RO-1
RESTORE- Nicotinamide Riboside supplementation to increase NAD⁺ levels and overcome mitochondrial dysfunction and inflammation that accelerate cellular aging in HIV
Total Direct Costs: \$2,489,056
Review pending

MPI (Sherman/Kottlil)
NIAID/NIH U01
CCR2/5 antagonism to reverse liver fibrosis in HIV patients
Total Direct costs: \$4,657,350
Review pending

Coinvestigator (PI: David Riedel, IHV)
1 U01 CA275052-01 - KOMESHA Kenya's Optimized Micro Elimination Strategy for HCV and Hepatocellular Cancer in PLWH
Total Direct Costs: \$249,986
Scored, not funded (resubmission pending)

Principal Investigator (MPI: Kottlil/Ghosh)
RO1DA065079 Impact of opioid use disorder on mitochondrial dysfunction among antiretroviral therapy-receiving aging people with HIV
Total Direct Costs: \$2,506,087
Review pending

Principal Investigator (MPI: Kottlil/Khanam)
RO1AI189880 Delineating adaptive immune mechanisms on HDV persistence, progression, and clearance
Total Direct Costs: \$2,302,456
Review pending

Principal Investigator (MPI Kottlil/Mathur)

RO1AG099725 CD38 mediated mitochondrial dysfunction and inflammation contribute to frailty in people with HIV (CIMULATE)
 Total Direct costs: \$2,403,065
 Review pending

Active Non-NIH Grants

04/01/2023 - 03/31/2026	Co- Principal Investigator Expanding linkage to Hepatitis B and C care, medication assisted treatment, and harm reduction services among people who inject drugs in Tanzania (the ANCHOR model) John C Martin Foundation Grant Total Direct Cost: \$222,172
04/01/2024 - 03/31/2026	Co- Principal Investigator Long term outcomes of HCV treated PWID patients (LOOP) John C Martin Foundation Grant Total Direct Cost: \$170,000
03/15/2023 - 03/14/2026	Co- Principal Investigator A Pilot interventional study to develop micro-elimination of hepatitis C in prisons (ECLIPSE) AbbVie investigator-initiated grant Total Direct Cost: \$210,000
02/15/2023 - 02/14/2026	Co- Principal Investigator An integrated care model for HCV care continuum in Tanzania John C Martin Foundation Grant Total Direct Cost: \$225,000
02/15/2024 - 02/14/2026	Co- Principal Investigator Task shifting of HCV and HBV care in Islamabad, Pakistan John C Martin Foundation Grant Total Direct Cost: \$69,000
02/15/2024 - 02/14/2026	Co- Principal Investigator Task shifting of HCV and HBV care in Uzbekistan John C Martin Foundation Grant Total Direct Cost: \$100,000
10/01/2018 - 09/31/2026	Co-Investigator Prospective Study to Determine immune synergy in Chronic Hepatitis B Infection

Arbutus Pharmaceuticals, Investigator Initiated Grant
Total Direct Costs: \$312,000

NIH K Grants

05/01/2024 - 04/30/2026	Co-Investigator, 1%, Principal investigator: Elana Rosenthal MD NIH Office of AIDS Research HHS Total Direct Costs: \$152,000 Role: Co-Investigator
10/01/2019-10/01/2022	K-12 Pittsburgh HIV Mentored Training for Investigation of Comorbidities and Cure (HIVMeTriCC) NIH/NHLBI: 5K12HL143886-02 Translational research in reducing cardiac morbidities in PLWH Awardee: Poonam Mathur DO, MPH Direct costs: \$130,000 Role: Primary Mentor
07/01/2020-06/01/2022	UMB ICTR Clinical and Translational Science Awards (KL2) NIH/NHLBI: 5K12HL143886-02 Functional cure for chronic hepatitis B Awardee: Lydia Tang MBBS Direct costs: \$130,000 Role: Primary Mentor
05/15/2017-05/14/2022	NHLBI K23 award Elucidating Hepatitis C Infection as a Risk Factor for Coronary Heart Disease in HIV-Infected Patient NIH/NHLBI: K23 HL133358-01A1 Awardee: Shashwatee Bagchi MD Direct costs: \$135,000 Role: Primary Mentor
03/12/2016-03/11/2021	NIAID K08 award Mechanisms of viral clearance of hepatitis C with DAAs NIH/NIAID K08AI121348 Awardee: Eric Meissner MD, Ph.D Direct Costs: \$130,000 Role: Primary Mentor
01/07/2019-01/06/2023	NIMH K23 award Mechanisms and Predictors of Neurocognitive Impairment in HIV infection NIH/NIAID 1K23MH118070-01A1 Awardee: Erin O'Connor MD

Direct Costs: \$135,000
Role: Primary mentor

TBD

NIAID K23 award
Mechanisms and Predictors of Neurocognitive Impairment in HIV infection
NIH/NIAID 1K23AI189218-01A1
Awardee: Omar Harfouch MD
Direct Costs: \$135,000
Role: Mentor

Completed Grants at University of Maryland

09/15/2018 – 09/14/2029 Principal investigator; PI: Kottlil, University of Maryland
“A novel initiative to develop treatment strategies to remove craving for substance use disorders in patients with SUD”
This is a special NIH director’s HEAL initiative award with six-year funding to develop anti-craving therapeutics.
NIH Director’s HEAL Initiative/ NIAID
NIH SEARCH RTOP, HHSN27200027
Total Direct Costs: \$14,609,600.00
Role: Scientific Director

09/15/2023-09/14/2026 Co-investigator 2%, PI: Kevin Cullen
Broadly Neutralizing antibodies for COVID-19
NIH/NCI, 3P30CA134274-13S2
Total direct Costs, \$150,000
Role: Co-investigator

10/01/2020-09/30/2025 Principal Investigator, 2% TUD
Correlating Clinical and Radiologic Efficacy of a Novel TUD Agent in PLWH
NIH Bench to bedside award
NIH, NIDA RO1 DA043396-04W1
Total Direct Costs: \$110,000
Role: Principal Investigator

09/29/24 - 09/28/2029 Principal Investigator, 2%
NIH Office of AIDS Research/CCMD/CC/NIH
HHS, Contract 75N90020P00707
Total Direct Costs: \$546,098
Role: Principal Investigator

7/07/2017 - 07/06/2021 Principal Investigator
Evaluation of immune correlates of Phase 1b TLR8 Study

Gilead Sciences Inc
Total direct costs: \$436,600

04/12/2017 – 04/13/2022 Principal Investigator
A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection
Gilead Sciences Inc.
Total direct cost: \$45,126

07/01/2016 - 01/5/2021 Principal Investigator
Geomapping Resistance and Viral Transmission in Risky Populations (GRAVITY)
Gilead Sciences, Inc., Investigator Initiated Grant
Total Direct Costs: \$593,658

01/13/21—1/12/2023 Co-Investigator, 2% PI: Eleanor Wilson
Title: Neuroimaging and Behavioral Studies to Assess for Neuroinflammation in COVID-19 During Convalescence
NIH/NINDS, R21 NS121615-01
Total Direct Costs: \$230,345
Role: Develop and Maintain COVID-19 long hauler cohort

11/01/2014 - 1/31/2020 Co-Investigator, 5%; PI: Ken Sherman, University of Cincinnati
Antiretroviral Toxicity in HIV/HCV infection
NIH/NIAID, RO-1 Grant 2R01AI065256 - 06A1
Total Direct Costs: \$196,550
Role: Mechanistic studies of the grant

11/01/2014 - 8/31/2020 Co-Investigator, 5%; PI: Ken Sherman, University of Cincinnati
Title: Hepatitis E in HIV-infected Patients
NIH/NIDDK, RO-1DK108362 Grant
Total Direct Costs: \$45,310
Role: Provide HIV patients cohort for testing

09/15/2017 – 5/31/2023 Principal Investigator, 15%; PI: Kottlil, University of Maryland
Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs.
NIH/NIDA, 3R01DA043396-02S1
Total Direct Costs: \$1,931,538
Role: Principal Investigator

06/01/2020 – 05/31/2021 Principal Investigator, 5%; PI Kottlil, University of Maryland
Immune correlates of COVID-19 in OUD
NIH/NIDA, 3R01DA043396-04S1
Total Direct Costs: \$100,000

Role: Principal Investigator

- 09/01/2020-08/31/2020 Clinical Principal Investigator 2%: MPI: Pan Zheng
CD24Fc for COVID-19
NIH/NCI, 3R44CA246991-02W1
Total Direct Costs: \$250,000
Role: Clinical Principal Investigator
- 11/01/2014 - 10/31/2020 Co-Investigator, 5%; PI: Peter Stock, University of San Francisco
A Pilot Study to Assess Safety, Tolerability, and Efficacy of
Sofosbuvir and Ledipasvir for Hepatitis C Treatment in HIV/HCV
Coinfected Subjects Pre or Post Liver Transplant (STOP-CO)
NIH/NIAID-Division of AIDS P0500506, U Grant
Total Direct Costs: \$312,413
Role: Site PI and bench-work PI
- 09/29/2014 - 09/28/2015 Principal Investigator
NIH Contract for District of Columbia Program for AIDS Progress
Office of AIDS Research/CCMD/CC/NIH HHSN269201400012C
Total Direct Costs: \$689,625
- 01/01/2015 - 12/31/2019 Principal Investigator
Phase IV Pilot Study to Assess Community-based Treatment
Efficacy in Chronic Hepatitis C Monoinfection and Coinfection
with HIV in the District of Columbia (ASCEND)
Gilead Sciences, Inc. Investigator Initiated Grant
Total Direct Costs: \$1,076,750
- 09/15/2015 - 12/31/2016 Principal Investigator
A Prospective Study to Determine Immunophenotypes and Cellular
Responses in the Setting of Hepatitis B Infection
Medimmune, Inc., Investigator Initiated Grant
Total Direct Costs: \$400,000
- 03/01/2016 - 04/30/2018 Principal Investigator
IHV-Rwanda Hepatitis C Education Collaboration (IRCEC) for
HCV provider Training
Gilead Sciences, Inc., Investigator Initiated Grant
Total Direct Costs: \$165,000
- 05/01/2016 - 04/30/2020 Principal Investigator
Tenofovir Alafenamide for HBV – A Longitudinal Study (TEMUL)
Gilead Sciences, Inc., Investigator Initiated Grant
Total Direct Costs: \$645,970

05/01/2016 - 04/30/2019 Principal Investigator
A Pilot Study to Evaluate a Salvage Therapeutic Regimen for HCV Patients Previously Failed Directly Acting Antiviral Therapy (RESOLVE)
Gilead Sciences, Inc., Investigator Initiated Grant
Total Direct Costs: \$3,000,000

07/01/2016 - 06/30/2017 Principal Investigator
Community-based Hepatitis B, C and HIV Education, Screening and Linkage in New Patient Populations (TIGER-FOCUS)
Gilead Sciences, Inc, FOCUS Program Grant
Total Direct Costs: \$160,000

07/01/2016 - 06/30/2020 Principal Investigator
Geomapping Resistance and Viral Transmission in Risky Populations (GRAVITY-FOCUS)
Gilead Sciences, Inc, FOCUS Program Grant
Total Direct Costs: \$199,000

07/01/2016 - 06/30/2020 Principal Investigator
A Novel Model of Hepatitis C Treatment As Anchor to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior (ANCHOR)
Gilead Sciences, Inc., Investigator Initiated Grant:
Total Direct Costs: \$390,543

07/01/2016 - 06/30/2020 Principal Investigator
Prospective Study to Determine Immunophenotypes and Humoral Responses in the Setting of Chronic Hepatitis B Infection
Arbutus Pharmaceuticals, Investigator Initiated Grant
Total Direct Costs: \$313,059

09/29/2015 - 09/28/2016 Principal Investigator
NIH Contract for District of Columbia Program for AIDS Progress Office of AIDS Research/CCMD/CC/NIH HHSN269201400012C
Total Direct Costs: \$1,277,640

09/29/2016 - 09/28/2017 Principal Investigator
NIH Contract for District of Columbia Program for AIDS Progress Office of AIDS Research/CCMD/CC/NIH HHSN269201400012C
Total Direct Costs: \$2,208,255

01/15/2017 - 12/31/2018 Principal Investigator
HCV Training Grant-IMPHAL, India
The Global Virus Network initiative
Gilead Sciences Grants
Total direct costs: \$148,487

01/15/2017 - 12/31/2019 Principal Investigator
HBV Screening Study-Tezpur, India

The Global Virus Network initiative
 John C Martin Foundation Grant
 Total direct costs: \$218,654

03/12/2017 - 03/11/2019 Principal Investigator
 Immune Correlates of HBV infection
 Gilead Sciences Inc
 Total direct costs: \$202,897

03/12/2017 - 03/11/2019 Principal Investigator
 Truculture Methodology to Evaluate ex vivo immune responses
 Gilead Sciences Inc
 Total direct costs: \$77,449

04/01/2017 - 03/31/2020 Principal Investigator
 A Novel Model of Hepatitis C Treatment As Anchor to Prevent
 HIV, Initiate Opioid Substitution Therapy, and Reduce Risky
 Behavior (ANCHOR 2)
 Merck Inc (MISP)
 Total Direct Costs: \$126,235

04/15/2017 - 04/14/2019 Principal Investigator
 Impact of Immune Suppression on HCV treatment response
 Merck Inc (MISP)
 Total direct costs: \$245,234

06/24/2017 - 06/23/2020 Principal Investigator
 Evaluation of immune correlates of Phase Ia TLR8 Study
 Gilead Sciences Inc
 Total direct costs: \$342,347

08/10/2017 - 08/09/2020 Principal Investigator
 A single site open label study to evaluate the safety and efficacy of
 grazoprevir/elbasvir for Egyptian patients with hepatitis C genotype
 4 infection and advanced renal impairment
 Merck Inc (MISP)
 Total direct costs: 399,713

09/01/2017 - 09/01/2019 Principal Investigator
 An omnibus clinical protocol to evaluate hepatitis B infection
 Roche Inc
 Study support includes HBsAg kits
 Total direct costs: \$73,267

02/12/2018 - 02/11/2020 Co-Investigator
 CoCrystal Trial to Explore Ultrashort duration of HCV therapy
 CoCrystal Inc

Total Direct Cost: \$654,549

02/15/2018 - 02/14/2020 Principal Investigator
Cardiovascular changes associated with HCV infection
NIH Bench to bedside Award (NIDA supplement)
Total Direct Costs: \$145,000
Total costs: \$370,000

04/02/2018 - 04/01/2020 Principal Investigator
APOSTLE
Gilead Sciences Inc
Total direct cost: \$249,056

06/15/2018 - 06/14/2020 Co- Principal Investigator
Phase 2b Clinical trial to evaluate TLR8 agonist for chronic HBV
Gilead Sciences Inc
Total Direct Cost: \$765,098

Completed Grants at National Institutes of Health

07/01/2001 - 09/14/2014 Principal Investigator
#AI000886 titled "Role of Innate Immunity in the Initiation and Pathogenesis of HIV infection"
NIAID Intramural Award
Annual Budget: \$90,000
Total Budget: \$1,170,000

07/01/2001 - 09/14/2014 Principal Investigator
AI000390 titled "The Therapeutic Strategies for the Management of HIV/HCV Co-infection"
NIAID Intramural Award
Annual Budget: \$40,000
Total Budget: \$520,000

07/01/2001 - 09/14/2014 Collaborating Investigator (Co-Inv, PI, Dr. Tae-Wook Chun Ph.D)
#AI000885 titled "Immunologic and Virologic Strategies Directed toward HIV infection"
NIAID Intramural Award

07/01/2001 - 09/14/2014 Collaborating Investigator (PI: Dr. Sharon Wahl Ph. D)
#DE000513 titled "Role of Monocytes in AIDS and as Targets of Antiviral Therapy"
NIDCR Intramural Award

07/01/2001 - 09/14/2014 Collaborating Investigator (PI: Dr. Susan Moir Ph. D)
#AI000825 titled "Role of B lymphocytes in HIV infection and Pathogenesis"
NIAID Intramural Award

- 07/01/2001 - 09/14/2014 Collaborating Investigator (PI: Dr. Frank Maldarelli MD, Ph.D)
BC010527 titled "Characterization of the Genetic Diversity of HIV-1 in Infected Individuals"
NCI Intramural Award
- 07/01/2001 - 09/14/2014 Collaborating Investigator (PI: Dr. Frank Maldarelli MD, Ph.D)
BC010528 titled "In Vivo assessment of Residual Drug Activity in Patients with Genotypic and Phenotypic resistance"
NCI Intramural Award
- 07/01/2001 - 09/14/2010 Collaborating Investigator
#BC010819 titled "HIV Genetic Variation Infected individuals"
NIAID
- 07/01/2003 - 09/14/2014 Collaborating Investigator (PI: Dr. David Kleiner MD, Ph.D)
ZIC010687 titled "Hepatic Histology Core Laboratory Research"
NCI Intramural Award
- 10/01/2005 - 09/30/2007 Collaborating Investigator
Persistent HIV Reservoirs in Infected Patients Receiving Effective Antiviral Therapy for Prolonged Periods of Time: Delineation of Mechanism and Source of Viral Replication and Execution of a New Therapeutic Strategy
NIH Bench to Bedside
Total budget: \$400,000
- 10/01/2006 - 09/30/2008 Collaborating Investigator
Genetic Characteristics of HIV-1 during Suppressive Antiretroviral Therapy
NIH Bench to Bedside
Total budget: \$400,000
- 10/01/2006 - 09/30/2008 Collaborating Investigator
Intensification of Antiretroviral Therapy Using HIV Integrase Inhibitor (MK-0518) to Assess Decay of Viral Reservoirs in Peripheral Blood and Gut-Associated Lymphoid Tissue of Chronically Infected Patients
NIH Bench to Bedside
Total budget: \$400,000
- 07/01/2007 - 09/14/2011 Collaborating Investigator
#AI001039 titled Antiviral activities of Human Interferons
NIAID Intramural Award
- 10/01/2007 - 09/30/2008 Principal Investigator
High-Throughput Serum Protein Analysis to Predict Therapeutic Responses of Chronic Hepatitis C
NIH DIR Supplemental Award
Total budget: \$60,000
- 10/01/2009 - 09/30/2010 Principal Investigator
Ethnicity on Host Molecular factors that determine HCV Treatment

Responses to Peg interferon-alpha and Ribavirin
 Office of AIDS Research Cycle 3 Award
 Total budget: \$100,000

10/01/2009 - 09/30/2010 Principal Investigator
 Role of IFNAR2a on IFN Non-responsiveness of HIV/HCV-
 infected African Americans
 Office of AIDS Research Cycle 2 Award
 Total budget: \$75,000

10/01/2009 - 09/30/2010 Principal Investigator
 Immunoregulation of HBV specific T cell responses in relation to
 the antiviral effect of HBV therapeutics in HBV mono and
 HIV/HBV co-infected subjects
 NIH DIR Supplemental Award
 Total budget: \$70,000

10/01/2010 - 09/30/2011 Principal Investigator
 HIV, Hepatitis and Co-morbidities First-NIH Indo International
 Conference Award
 Office of AIDS Research Cycle 3 Award
 Total budget: \$90,000

10/01/2010 - 09/30/2011 Principal Investigator
 Scientific support for NIH-District of Columbia Program for AIDS
 Progress (DC-PFAP)
 Office of AIDS Research
 Total budget: \$100,000

10/01/2011 - 09/30/2012 Principal Investigator
 Hepatitis Research in HIV patients
 Office of AIDS Research Cycle 3 Award
 Total budget: \$100,000

10/01/2011 - 09/30/2012 Principal Investigator
 Scientific support for NIH-District of Columbia Program for AIDS
 Progress (DC-PFAP)
 Office of AIDS Research Cycle 3 Award
 Total budget: \$125,000

10/01/2011 - 09/30/2013 Principal Investigator
 Effect of CCR5 Blockade on liver disease progression in HIV
 infected subjects
 NIH Bench to Bedside
 Total budget: \$470,000

10/01/2012 - 09/30/2013 Principal Investigator
 Scientific support for NIH-District of Columbia Program for AIDS
 Progress (DC-PFAP)
 Office Of AIDS Research
 Total budget: \$135,000

10/01/2012 - 09/30/2014 Co-Principal Investigator (Co-PI: Dr. Caryn Morse MD)
Effect of Lysyl Oxidase-2 inhibition on progression of liver fibrosis”
NIH Bench to Bedside Award
Annual Budget: \$235,000
Total budget: \$470,000

10/01/2012 - 09/30/2014 Principal Investigator
Programmed Death Receptor- Blockade to treat chronic hepatitis B in HIV infection
NIH Bench to Bedside Award
Annual Budget: \$235,000
Total Budget: \$470,000

10/01/2012 - 09/30/2014 Collaborating Investigator (PI: Colleen Hadigan MD)
Development of Magnetic resonance Spectroscopy to Assess Liver Fat Content
NIH Bench to Bedside Award
Annual Budget: \$235,000
Total Budget: \$470,000

01/01/2013 - 09/14/2014 Principal Investigator
Treatment of HIV/HCV Coinfected Subjects with Fixed Dose Combination CRADA with Gilead Sciences, Inc.
Total Budget: \$501,000

01/01/2013 - 09/14/2014 Principal Investigator
Treatment of HCV infection using multiple combinations of Directly Acting Agents
CRADA with Gilead Sciences, Inc.
Total Budget: \$300,000

10/01/2013 - 09/30/2014 Principal Investigator
Scientific support for NIH-District of Columbia Program for AIDS Progress (DC-PFAP)
Office Of AIDS Research
Total Budget: \$125,000

Active Clinical Trials

2007 - present Principal Investigator of NIAID Clinical Trial Protocol #07-I-N135 titled “Analysis of stored samples obtained from previously terminated protocols” Co-investigator since 9/15/2014.

2010 - present Principal Investigator of NIAID Clinical Trial Protocol #11-CC-0152, a Natural history study, titled “HIV-Liver Disease Natural History Prospective Cohort” Co-investigator since 9/15/2014.

2013 - present Associate Investigator of NIAID Clinical Trial Protocol #13-I-0140 titled “A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime, rVSV Booster

- Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection”.
- 2015 - present Principal Investigator for Clinical Trial # NCT02995252, named “An Omnibus Protocol to Characterize Patients with Hepatitis B and C”. (HOPE/TEMUL). Co-investigator since 2016.
- 2015 - present Co-investigator for Clinical Trial# NCT02339038, named “A Phase IV Pilot Study to Assess Community-based Treatment Efficacy in Chronic Hepatitis C Monoinfection and Coinfection with HIV in the District of Columbia”. (ASCEND)
- 2015 - present Co-investigator of Clinical Trial # NCT02403674, Merck Sharp & Dohme Corp. named “A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects”. (DRIVE-AHEAD).
- 2015 - present Co-investigator of Clinical Trial # NCT02397096, Merck Sharp & Dohme Corp. named “MK1439A-024, A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors”. (DRIVE-SHIFT)
- 2015 - present Principal Investigator of “A Prospective Cohort Study to Assess Treatment Efficacy in Chronic Hepatitis C Mono-infection and Co-infection with HIV”.
- 2015 - present Sub-Investigator of Clinical Trial # NCT02533934, University of California, San Francisco named “Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant”. (STOP-CO)
- 2016 - present Principal Investigator for “A Pilot Study to Evaluate HCV Therapy in Resource Limited Setting”. (PIONEER INDIA)
- 2016 - present Co-investigator for Clinical Trial # NCT02902120, named “Host Mechanisms Involved in Achieving SVR Using a Fixed Dose Combination of grazoprevir and elbasvir in Treatment of Chronic Hepatitis C Genotype 1 in Non-cirrhotic Patients with Chronic Kidney Disease Before and After Renal Transplantation.
- 2016 - present Co-investigator for Clinical Trial # NCT02881762, named “A Pilot Study to Evaluate Anti-HCV Effect of Maraviroc in HIV/HCV Co-infected Patients”.(MAVERIC)
- 2016 - present Co-investigator for “Geomapping Resistance and Viral Transmission in Risky Populations”. (GRAVITY)

- 2017 - present Co-Investigator for Clinical Trial #NCT03312023, named “A Phase II Open-Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects with Hepatitis B Virus Infection”. (APOSTLE)
- 2017 - present Co-investigator for Clinical Trial # NCT02990312, named “The Effect of Sirolimus plus Maraviroc on the Expression of Chemokine Receptor 5 and the HIV-1 Viral Reservoir in HIV-Infected Renal Transplant Recipients”.
- 2017 - present Principal Investigator for Gilead Sciences, Inc. “A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection”.
- 2017 - present Co-investigator for Clinical Trial# NCT03221309, named “A Novel model of Hepatitis C Treatment as Anchor to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior”. (ANCHOR)
- 2017 - present Co-investigator for “Elucidating Chronic Hepatitis C Infection as a Risk Factor for Coronary Heart Disease in HIV-Infected Patients”.
- 2018 - present Co-investigator for Clinical Trial #NCT03501550, named “An Open-Label Phase 2a Study Evaluating the Safety and Efficacy of Combination Treatment with 2 Weeks of the Non-Nucleoside Inhibitor CDI-31244 Plus 6 Weeks of Sofosbuvir/Velpatasvir in Subjects with Chronic Hepatitis C Genotype 1 Infection”.
- 2018 - present Principal Investigator for Clinical Trial # NCT03381859, named “A Single-site, Open-label, Non-comparator Clinical Trial to Eliminate HCV-infection in Treatment-naïve, Egyptian Patients with End-stage Renal Disease on Renal Dialysis, with Chronic Hepatitis C Genotype 4 Infection using a 12-week Course of Once-daily Single Oral Tablet of elbasvir/grazoprevir”. (CLEAR-C4)
- 2018 - present Co-investigator for Clinical Trial #NCT03491553, Gilead Sciences, Inc. named “A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Virally-Suppressed Adult Subjects with Chronic Hepatitis B.”
- 2018 - present Co-investigator for Clinical Trial #NCT03212521, AbbVie Inc. named “Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of glecaprevir/pibrentasvir in Treatment Naïve Adults with Chronic Hepatitis C Virus Genotypes 1 – 6 Infection and Aspartate aminotransferase to Platelet Ratio Index ≤ 1 ”. (M16-133)
- 2018 - present Vice Chair, for ACTG Clinical trial titled “A Phase II Randomized Study Assessing the Safety and Efficacy of 24 Weeks of REP 2139-Mg Monotherapy, Followed by 48 Weeks of Combined Therapy with REP 2139-Mg and Pegylated Interferon Alpha-2a in Participants with HBeAg

- Negative Chronic HBV Infection Suppressed with Nucleos(t)ides. A Multicenter Trial of the AIDS Clinical Trials Group (ACTG).
- 2018 - present Co-investigator, for protocol “Cardiovascular disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication”. (CHROME)
- 2018 - present Co-Investigator for Clinical Trial # NCT03439254, Intercept Pharmaceuticals named “Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis”. (REVERSE)
- 2022- Principal Investigator for A pilot clinical trial to use irradiated malarial sporozoites to induce intrahepatic anti-HBV immunity for functional cure (AVANTE-GARDE)-Battleship therapeutics
- 2022 Coinvestigator for CHOICE STAR multicenter clinical trial for reducing infectious diseases complications in people who inject drugs

Completed Clinical Trials

- 2001 - 2012 Principal Investigator of NIAID Clinical Trial Protocol #02-I-0202 titled “Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral naïve Primary and Chronic HIV-Infected individuals”
- 2001 - 2006 Principal Investigator of NIAID Clinical Trial Protocol #01-I-0194, Phase III study, titled “A Non-Randomized, Open label, Study to Assess Hepatitis C Kinetics in Predicting the Clinical Response in Patients with Hepatitis C infection Co-infected with HIV-1 Treated with Peginterferon Alpha-2b and Ribavirin”
- 2001 - 2003 Principal Investigator of NIAID Clinical Trial Protocol #02-I-0139, a Phase III study, titled “A Randomized, Controlled Study to Assess the Impact of Highly Active Antiretroviral Therapy to Hepatitis C Therapy in Patients Co-infected with HIV-1 and Treated with Peginterferon Alpha-2b and Ribavirin”
- 2002 - 2006 Associate Investigator of NIAID Clinical Trial Protocol #03-I-0310 titled “Immune Response to Influenza Vaccination in HIV-infected Individuals”
- 2002 - 2006 Associate Investigator of NIAID Clinical Trial Protocol #02-I-0013 titled “A Randomized, Controlled Trial of Short Cycle Intermittent Versus Continuous HAART for the Treatment of Chronic HIV Infection”
- 2002 - 2006 Associate Investigator of NIAID Clinical Trial Protocol #00-I-0020 titled “Immunologic and Virologic Studies of Intermittent versus Continuous HAART in the Treatment of HIV Disease”
- 2003 - 2013 Principal Investigator of NIAID Clinical Trial Protocol #92-I-0125 titled “Analysis of Peripheral Blood Versus Lymphoid Tissue among HIV-Infected and Normal Patients”

- 2003 - 2014 Principal Investigator of NIAID Clinical Trial Protocol #91-I-0140 titled “Studies of the Pathogenesis of HIV infection in Human Peripheral Blood Cells and/or Reproductive Fluids in HIV-infected and HIV-uninfected Volunteers”
- 2003 - 2015 Principal Investigator of NIAID Clinical Trial Protocol #04-I-0086 titled “Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on HCV-infected Patients”
- 2003 - 2005 Principal Investigator of NIAID Clinical Trial Protocol #04-I-0149, a Phase I study, titled “An Open label Trial to Assess the Safety and Tolerability of Daclizumab in HIV-infected Individuals”
- 2003 - 2007 Principal Investigator of NIAID Clinical Trial Protocol #04-I-0187, a Phase II study, titled “A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Twice-Weekly Peginterferon Alpha 2a and Ribavirin Induction Therapy for Chronic Hepatitis C in Patients who are Coinfected with HIV-1”
- 2003 - 2005 Principal Investigator of NIAID Clinical Trial Protocol #04-I-0097, a Phase II study, titled “A Randomized Controlled Study to Evaluate the Safety and Efficacy of Long-Term Peginterferon Alpha 2a for Treatment of Chronic Hepatitis C Patients Coinfected with HIV-1”
- 2007 - 2011 Principal Investigator, Clinical Trials Agreement with Human Genome Sciences Inc. Albinterferon for HIV/HCV Coinfected Subjects
- 2007 - 2010 Principal Investigator of NIAID Clinical Trial Protocol #07-I-0001, a Phase I study, titled “An Open label Trial to Assess the Safety and Tolerability of Albuferon 1800mcg every two weeks along with ribavirin in HCV/HIV-infected Individuals”
- 2007 - 2010 Associate Investigator of NIAID Clinical Trial Protocol #08-I-0034 titled “Validation of (1)H-Magnetic Resonance Spectroscopy for Quantification of Hepatic Triglyceride Content”
- 2009 - 2012 Principal Investigator of NIAID Clinical Trial Protocol #10-I-N184, a Natural history study, titled “Liver Fibrosis Progression in African Americans with HIV-HCV Co-Infection”
- 2009 - 2012 Principal Investigator of NIAID Clinical Trial Protocol #10-I-0159, a Phase I study, titled “An Open Label Study to Evaluate the Safety, Efficacy, Viral Kinetics Genetic, Epigenetic, and Proteomic Expression of Weekly Peg interferon Alpha 2a and Ribavirin Therapy for Chronic Hepatitis C in Latino Subjects with and without HIV Coinfection”
- 2009 - 2012 Principal Investigator of NIAID Clinical Trial Protocol #10-CC-0183, a Phase I study, titled “An Open label Trial to Assess the Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders”

- 2010 - 2011 Principal Investigator, Clinical Trials Agreement with Pharmasset Inc. PSI 7977 with ribavirin to treat hepatitis C genotype 1 infected subjects
- 2011 - 2012 Associate investigator of NIAID Clinical Trial Protocol #12-I-0173 titled "A Long-Term Follow-up Registry of Subjects Who Did Not Achieve Loss of S Antigen (HBsAg) and Sustained HBV Viral Load Reduction Below the Limit of Quantitation (BLQ) in Gilead-Sponsored Trials of GS-9620 in Subjects with Chronic Hepatitis B Infection"
- 2011 - 2012 Associate investigator of NIAID Clinical Trial Protocol #12-I-0172 titled "Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects with Chronic Hepatitis B Virus Infection"
- 2011 - 2012 Associate investigator of NIAID Clinical Trial Protocol #12-I-0171 titled "Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in Naive Subjects with Chronic Hepatitis B Virus Infection"
- 2011 - 2012 Associate investigator of NIAID Clinical Trial Protocol #12-I-0115 titled "Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in naive Subjects with Chronic Hepatitis C Virus Infection"
- 2011 - 2013 Principal Investigator, Clinical Trials Agreement with Gilead Sciences Inc. TLR-7 agonist to treat chronic hepatitis C patients.
- 2011 - 2013 Principal Investigator, Clinical Trials Agreement with Gilead Sciences Inc. TLR-7 agonist to treat chronic hepatitis B treatment experienced patients.
- 2011 - 2013 Principal Investigator, Clinical Trials Agreement with Gilead Sciences Inc. TLR-7 agonist to treat chronic hepatitis B treatment naive patients.
- 2011 - 2014 Principal Investigator, Clinical Trials Agreement with Merck Inc. Peg interferon alfa, ribavirin and boceprevir for treating HIV/HCV coinfecting subjects
- 2011 - 2014 Principal Investigator of NIAID Clinical Trial Protocol #11-I-0258, a Phase II study, titled "A Randomized Controlled Study to Assess Safety, Tolerability and Efficacy of PSI-7977 alone or in combination with RBV in HCV Genotype 1-infected Treatment Naive Patients"
- 2011 - 2013 Principal Investigator of NIAID Clinical Trial Protocol #11-CC-0253, a Phase III study, titled "An Open Label, On-Treatment Trial, to Assess the Effect of HIV Coinfection on Therapeutic Responses using Boceprevir, Peg-Interferon-alfa 2b and Ribavirin in HCV Genotype 1a Treatment Naive Subjects"
- 2012 - 2014 Principal Investigator, Clinical Trials Agreement with Gilead Sciences Inc. Anti-LOXL2 to treat chronic liver fibrosis patients

- 2012 - 2014 Principal Investigator, Corporate Research and Development Agreement with Gilead Sciences Inc. Evaluation of multiple combination therapy to treat chronic hepatitis C patients
- 2012 - 2014 Principal Investigator, Corporate Research and Development Agreement with Gilead Sciences Inc. Combination therapy to treat chronic hepatitis C patients in HIV-infected subjects
- 2012 - 2014 Principal Investigator of NIAID Clinical Trial Protocol #14-I-0157, a Phase II study, titled “An open label Trial to Assess Safety, Tolerability and Efficacy of GS-7977 in combination with GS-5885 in HIV/HCV Genotype 1-infected Treatment naive patients”.
- 2012 - 2016 Principal Investigator of NIAID Clinical Trial Protocol #13-I-0066, a Phase II study, titled “A pilot study to evaluate the safety and efficacy of multiple anti-HCV combination therapy in chronically infected hepatitis C genotype 1 subjects who are naïve or null responders to peg-interferon alpha based therapy” Co-investigator since 9/15/2014
- 2013 - 2014 Principal Investigator, Clinical Trials Agreement with Bristol Myers Squibb Inc. Asunaprevir with Daclatasvir for treatment of hepatitis C in HIV infected subjects
- 2015 - 2016 Co-investigator of “Chronic Hepatitis C as Risk Factor for Increased Burden of Cardiovascular Disease in HIV-Infected Patients”.
- 2015 - 2016 Principal Investigator of Clinical Trial # NCT02487012, Gilead Sciences, Inc. named “A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection”. (ASTRAL-5)
- 2015 - 2016 Principal Investigator of “Use of a Luciferase Immunoprecipitation Systems (LIPS) Array to Characterize Isolated Hepatitis B Core Antibody Positivity”.
- 2015 - 2016 Principal Investigator of Clinical Trial # NCT02607735, Gilead Sciences, Inc. named “Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy”. (POLARIS-1)
- 2015 - 2017 Principal Investigator of Clinical Trial # NCT02607800 , Gilead Sciences, Inc. named “A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subjects with Chronic HCV.” (POLARIS-2)
- 2015 - 2017 Principal Investigator of Clinical Trial # NCT02639338 , Gilead Sciences, Inc. named “A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-

- 9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis”. POLARIS-3).
- 2015 - 2017 Principal Investigator of Clinical Trial # NCT02639247, Gilead Sciences, Inc. named “Safety and Efficacy of SOF/VEL/GS-9857 FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor”. (POLARIS-4)
- 2015 - 2017 Principal Investigator of Clinical Trial # NCT01667081, Merck Sharp & Dohme Corp. named “Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir” (MK-5172-017)
- 2016 - 2019 Co-investigator for Clinical Trial # NCT02745535 named “Safety and Efficacy of Sofosbuvir, Velpatasvir and Voxilaprevir in Patients with Previous DAA Experience”. (RESOLVE)
- 2016 - 2018 Principal Investigator for “A Pilot Study to Evaluate a Qualitative Point of Care Test for HCV Nucleic Acid in Outpatient Hepatitis C Treatment Clinics”. (PIONEER)
- 2016 - 2018 Principal Investigator for Gilead Sciences, Inc. “A Long-Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection”.
- 2017 - 2018 Principal Investigator for “Immune Correlates of Long-term Success with DAA therapy in HCV/HIV Infected People Who Inject Drugs”.

US Patents

1. Patent Application Number: 63/637,170, filed 4/22/24. Title: “Quantitative PCR Assays for Detection of Porcine Viral RNAs After Xenotransplant” UMB Docket Number: AG-2024-061 (PR)

Publications

Peer-reviewed Journal Articles

1. Suresh K, Jayavardhanan KK, **Kottlil S**, Kuttappan C, and Vasudevan DM. Natural Killer Cell and Antibody Dependent Cellular Cytotoxicity in Gastric Carcinoma Patients: *Oncology Reports*. (1994), 1: 439.
2. Kutty KM, **Kottlil S**, and Andrews W. From Pseudocholinesterase to AIDS virus: *Medical Hypothesis* (1995), 45: 225.
3. **Kottlil S**, Gallant M, and Grant M. A Novel Mechanism of Activation-Induced Lymphocyte Death Related to HIV infection: *Mol. Biol. Cell*. (1996), 7:144a.
4. Marshall T, **Kottlil S**, Bowmer I, Trahey J, Pardoe I, and Grant MD. Characterization of Autoreactive Cytotoxic T Lymphocytes in HIV-infected individuals. *Can J. Infect. Dis* (1997), 8S: 62A.

5. **Kottlilil S**, Bowmer I, Trahey J, Campbell C, Gallant M, and Grant MD. The Relationship Between Circulating Autoreactive Cytotoxic T Lymphocytes Activity and Stage of Disease in HIV infection. *Can J. Infect. Dis.* (1997), 8S: 62A.
6. Grant MD, **Kottlilil S**, Marshall T, Gallant M, Pardoe I, Trahey J, Campbell C, and Bowmer I. Phenotypic, Functional and Molecular Genetic Changes in the CD8⁺ T cell population in HIV infection. *Immunol Lett.* (1997), 56:362.
7. Hamdalla H, **Kottlilil S**, and Fram R. The Limitations of Bone Scan vs. MRI for bone metastases. *Med Health R.I.* (2000), 83: 297.
8. **Kottlilil S**, Fram R, Schwartz S, Cortez KJ and Kesan S. Hypercalcemia and T-cell lymphoma with acquired immunodeficiency syndrome: Occurrence without human T-cell leukemia virus-I. *South Med. J* (2000), 93:894-897.
9. **Kottlilil S**, Gamberg J, Bowmer I, Trahey J, Howley C, Gallant M, and Grant MD. Human Immunodeficiency Virus type-1 Replication, Immune activation and Circulating Cytotoxic T Lymphocytes Against CD4⁺ T cells. *Grant. J. Clin. Immunol.* (2000), 23:175-186.
10. Papudesu B, Menon M, Yunis N, and **Kottlilil. S**. Invasive Pneumococcal disease. *Med Health R.I.* (2001), 84:89-91.
11. **Kottlilil S**, Bowmer MI, Trahey J, Howley JC, Gamberg J, and Grant MD. Fas/FasL-independent activation-induced cell death of T lymphocytes from HIV-Infected individuals occurs without DNA fragmentation. *Cell Immunol.* (2001), 214 :1-11.
12. Palmer S, Kearney M, Maldarelli F, **Kottlilil S**, Lucey D, Metcalf J, Rock D, VanHoutte M, Michels L, Hertogs K, Mellors J, and Coffin J. Genetics of HIV-1 populations in acute and chronic infection. *Antiviral Ther.* (2002), 7:S57.
13. **Kottlilil S**. NK cells in HIV-1 Infection: Role of NK cell-mediated non-cytolytic mechanisms in pathogenesis of HIV-1 infection. *Ind. J. Exp Biol.* (2003), 41:1219-1225.
14. **Kottlilil S**, Malech HL, Gill VJ, and Holland SM Infections with *Haemophilus Species* in Chronic Granulomatous Disease: Codependence of bacterial Catalase and Hydrogen Peroxide Production. *Clin Immunol* (2003), 106:226-30.
15. Cortez KJ, **Kottlilil S**, and Mermel L. Intracerebral tuberculomas misdiagnosed as neurosarcoidosis. *South. Med J.* (2003), 96:494-496.
16. **Kottlilil S**, Chun TW, Moir S, Liu S, Mclaughlin M, Hallahan CW, Maldarelli F, Corey L, and Fauci AS. Innate Immunity in HIV Infection: Effect of Viremia on NK Cell Function. *J. Infect Dis* (2003), 187:1038-45.
17. Moir S, Ogwaro KM, Malaspina A, Vasquez J, Donoghue ET, Hallahan CW, Liu S, Ehler LA, Planta MA, **Kottlilil S**, Chun TW, and Fauci AS. Perturbations in B cell responsiveness to CD4 T cell help in HIV-infected Individuals. *Proc. Natl. Acad. Sci. USA* (2003), 100:6057-62.
18. Malaspina A, Moir S, **Kottlilil S**, Hallahan CW, Ehler LA, Liu S, Planta MA, Chun TW, Fauci AS. Deleterious Effect of HIV-1 Plasma Viremia on B Cell Costimulatory Function. *J Immunol.* (2003), 170:5965-72.
19. Moir S, Donoghue ET, Pickeral OK, Malaspina A, Planta MA, Chun TW, Krishnan SR, **Kottlilil S**, Birse CE, Leitman SF, and Fauci AS. Continuous flow leukapheresis induces expression of stress genes in lymphocytes; impact on microarray analyses. *BLOOD* (2003), 102:3852-3.
20. Mavilio D, Benjamin J, Daucher M, Lombardo G, **Kottlilil S**. Planta MA, Marcenaro E, Bottino C, Moretta L, Moretta A, and Fauci AS. Natural Killer cells in HIV-1 infection:

- Dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. *Proc Natl Acad Sci, USA* (2003), 100:15011-15016.
21. **Kottlilil S**, Jagannatha S, Lu A, Liu S, McLaughlin M, Metcalf JA, Dewar R, Ternisky C, Koratich C, Maldarelli F, Masur H, and Polis MA. Changes in Hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals. *HIV Clin Trials* (2004), 5:25-32.
 22. Chun TW, Justement JS, Sanford C, Hallahan CW, Planta MA, Loutfy M, **Kottlilil S**, Moir S, Kovacs C, and Fauci AS Relationship between the frequency of HIV-specific CD8+ T cells and the level of CD38+CD8+ T cells in untreated HIV-infected individuals. *Proc Natl Acad Sci USA*. (2004), 101 8:2464-9.
 23. **Kottlilil S**, Polis MA, Kovacs JA. HIV Infection, Hepatitis C infection, and HAART: Hard Clinical Choices. *JAMA*. (2004), 292:243-50.
 24. **Kottlilil S**, Shin K., Planta M, Mclaughlin M, Hallahan CW, Ghany M, Chun TW, Sneller MC, and Fauci AS Expression of chemokine and inhibitory receptors on NK cells: Effect of immune activation and HIV viremia. *J. Infect Dis.* (2004), 189:1193-1198.
 25. Farel C, Suzman DL, McLaughlin M, Campbell C, Koratich C, Metcalf JA, Masur H, Robinson MR, Polis MA and **Kottlilil. S**. Serious Ophthalmic Pathology Compromising Vision in HCV/HIV Coinfected Individuals Treated With Peginterferon Alpha 2b and Ribavirin. *AIDS* (2004), 18:1804-1809.
 26. Moir S, Malaspina A, Pickeral OK, Donoghue ET, Vasquez J, Miller NJ, Krishnan SR, Planta MA, Turney JF, Justement JS, **Kottlilil S**, Dybul M, Mican JM, Kovacs C, Chun TW, Birse CE, and Fauci AS. Survival of B Cells of HIV-viremic Patients Mediated by Altered Expression of Receptors of the TNF Super family. *J Exp Med.* (2004), 200:587-99.
 27. Malaspina A, Moir S, Orsega S, Vasquez J, Miller NM, Donoghue ET, **Kottlilil S**, Gezmus M, Follman D, Vodeiko GM, Levandowski RA, Mican JM, and Fauci AS. Compromised B cell responses to influenza vaccine in HIV-infected individuals. *J Infect Dis.* (2005), 191:1442-50.
 28. Gupta N, Steenebeke T, Khazanie P, Chung E, Cruz C, Censoplano N, Van Ryk D, Schuck P, Sun P, Raedev S, Daucher M, **Kottlilil S**, Mavillio D, Chaikin M, Rabin R, Cicala C, Arthos J, and Fauci AS. Biological and Biochemical Characterization of a Highly Polymerized CD4-Ig Fusion Protein that Mediates Efficient Antibody Dependent Cell Mediated Cytotoxicity Against HIV Infected Cells. *Virology* (2005), 332:491-7.
 29. **Kottlilil S**, Jackson JO and Polis MA. Hepatitis B and C coinfection in HIV-infected individuals. *Ind J Med Res.* (2005), 121: 424-50.
 30. Fauci AS Mavilio D, and **Kottlilil S**. NK cells in HIV infection: Paradigm for Protection or Targets for Ambush. *Nat Rev Immunol.* (2005), 5: 835-43.
 31. Walsh TJ, Rollides E, Cortez K, **Kottlilil S**, Bailey J, and Lyman C Control, Immunoregulation, and Expression of Innate Pulmonary Host Defenses Against *Aspergillus fumigatus*. *Medical Mycology* (2005), 43:S165-72.
 32. Cortez K, Lyman CA, Kim HS, Rollides E, Yang, J, Lempicki R, **Kottlilil S**, and Walsh TJ. Kinetics of gene expression of innate host defense molecules in human monocytes infected with *Aspergillus fumigatus*. *Infect Immun* (2006), 74:2353-65.
 33. Pau A., McLaughlin M, Hu, Z., Polis MA, **Kottlilil. S**. Predictors of Hematopoietic Growth Factors Use in HIV/HCV Co-infected Patients Treated With Peginterferon Alpha 2b and Ribavirin. *AIDS Patient Care and STDs.* (2006), 20: 612-619.

34. Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, Huang DW, Wu L, Rehm CA, Masur H, Lane HC, Sherman KE, Fauci AS, and **Kottlilil S**. Gene expression profiles in HCV/HIV coinfection: Class prediction analyses prior to treatment predicts outcome of HCV therapy among HIV coinfecting individuals. *J. Infect Dis.* (2006), 193: 1172-7.
35. **Kottlilil S**, Shin K, Jackson JO, Reitano K, O'Shea MA, Yang J, Hallahan CW, Lempicki R, Arthos J, and Fauci AS. Innate immune dysfunction in HIV infection: Effect of HIV envelope-NK interactions. *J Immunol.* (2006), 176: 1107-14.
36. **Kottlilil S**, Wu L., Lempicki RA, Yang J, McLaughlin M, Hu Z, Koratich C, Reitano KN, Rehm C, Masur H, Wood B, Kleiner DE, and Polis MA. Hepatic histologic response (HR) to combination therapy among HCV/HIV coinfecting individuals: Interferon-induces HR independent of Sustained Virologic Response (SVR). *AIDS Res Hum Retrovir.* (2006), 22: 1091-8.
37. Malaspina A, Moir S, Rehm CA, **Kottlilil S**, Chaitt D, Falloon J, and Fauci AS. Idiopathic CD4⁺ T Lymphocytopenia is Associated with Increases in Immature/Transitional B Cells and Serum Levels of IL-7. *Blood.* (2007), 109:2086-8.
38. Myers JH, Justement JS, Hallahan CW, Blair ET, Sun YA, O'Shea MA, Roby G, **Kottlilil S**, Moir S, Kovacs C, Chun T-W, and Fauci AS. Impact of HIV on Cell Survival and Antiviral Activity of Plasmacytoid Dendritic Cells. *PLoS One* (2007), 2:458.
39. Nussenblatt V, McLaughlin M, Rehm C, Lempicki RA, Brann T, Yang J, Proschan M, Imamichi T, Koratich C, Neumann A, Masur H, Polis MA, **Kottlilil S**. Immunodeficiency and Intrinsic IFN Resistance Lead to Viral Breakthrough to HCV Therapy In HIV Coinfecting Patients. *AIDS Res Hum Retrovir.* (2007), 11:1354-9.
40. **Kottlilil S**, Jackson JO, Reitano KN, O'Shea MA, Roby G, Lloyd M, Yang J, Hallahan CW, Rehm CA, Arthos J, Lempicki RA, and Fauci AS. Innate Immunity in HIV Infection: Enhanced CD95-Mediated NK Cell Death and Turnover Induced by HIV Viremia. *J. AIDS.* (2007), 46:151-159.
41. Neumann AU, McLaughlin M, Koratich C, Rehm CA, Masur H, Polis MA, **Kottlilil S**. Differential Anti-Viral Effect of Peg-IFN a-2b on HIV and HCV in Treatment of HIV/HCV Co-Infected Patients. *AIDS* (2007), 21: 1855-65.
42. Highbarger HC, Hu Z, **Kottlilil S**, Metcalf JA, Polis MA, Vasudevachari MB, Lane HC, and Dewar RL. Comparison of the Abbott 7000 and the Bayer 340 systems for the measurement of HCV viral load. *J. Clin Micro.* (2007), 45:2808-12.
43. Cortez KJ, Rollides E, Quiroz-Telles F, Meletiadiis J, Antachapoulos C, Knudsen T, Buchanan W, Milanovich J, Sutton DA, Fothergill A, Rinaldi MG, Shea YR, Zaoutis T, **Kottlilil S** and Walsh TJ. Infections caused by *Scedosporium* Spp. *Clin Microbiol. Rev* (2008), 21; 157-197.
44. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra T, Conrad TP, Lempicki RA, Cruz C, Censoplano N, Chung E, Reitano KN, **Kottlilil S**, Goode D, Fauci AS. The HIV-1 Envelope Binds to $\alpha 4\beta 7$ integrin, the gut mucosal homing receptor. *Nat Immunol.* (2008), 9:301-309.
45. Tilton JC, Manion MM, Luskin MR, Johnson AJ, Patamawenu AA, Hallahan CW, Cogliano-Shutta NA, Mican JM, Davey, JT Jr., **Kottlilil S**, Lifson JD, Metcalf JA, Lempicki RA, and Connors M. HIV Viremia Induces Plasmacytoid Dendritic Cell Activation In Vivo and Diminished Interferon- α Production In Vitro. *J Virol* (2008), 82: 3997-4006.

46. Moir S, Malaspina A, Ho J, DiPoto A, **Kottlilil S**, Roby G, O'Shea A, Mican J, Chun TW, and Fauci AS. Increased B Cells Counts in Chronic HIV Disease during ART Is Associated with Disappearance of Apoptosis-prone B Cell Subsets. *J. Infect Dis* (2008), 197:572-9.
47. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, **Kottlilil S**, Moir S, Mican JA, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, and Fauci AS. Persistence of HIV in Gut Associated Lymphoid Tissue Despite Long-Term Antiretroviral Therapy. *J. Infect Dis* (2008) 197:714-720.
48. **Kottlilil S.** and Polis MA. HIV/AIDS Reviews *J. Urban Health* (2008), 1:6-10.
49. Suzman D, Hoehn G, Munson P, Ying X-A, McLaughlin M, Koratich C, Masur H, Rehm CA, Polis MA, and **Kottlilil S.** Biomarkers as predictors of liver fibrosis in HIV infection. *AIDS* (2008), 22:1432-9.
50. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O'Shea MA, Roby G, **Kottlilil S**, Arthos J, Proschan MA, Chun TW, Fauci AS. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. *J Exp Med.* (2008), 205:1797-805.
51. Allison RD, Katsounas A, Koxiol DE, Kleiner DE, Lempicki RA, Polis MA, and **Kottlilil S** Interleukin-15 Induced peripheral immune activation is associated with Hepatic Stellate Cell activation in HIV/HCV co-infected individuals. *J Infect Dis* (2009), 200:619-23.
52. **Kottlilil S.**, Yan MY, Reitano KN, Zhang X, Lempicki RA, Roby G, Daucher M, Yang J, Ghany M, Polis MA, and Fauci AS. HIV and HCV infections induce distinct immunologic imprints with implications for the pathogenesis of liver disease and therapeutic response to interferon-alpha. *Hepatology* (2009), 50:34-45.
53. Osinusi A., Kleiner DE, Wood B, Polis MA, **Kottlilil S.** Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection. *AIDS Patient Care and STDs.* (2009), 23:403-6.
54. Cortez K, Lyman CA, Kim HS, Rollides E, Yang, J, Lempicki R, **Kottlilil S**, and Walsh TJ. Comparative Genomics of Monocyte Response to *Aspergillus* and *Rhizopus* spp. *Infect Immun.* (2009), 21: 157-97.
55. Neis-Kraske E, Condoluci D, Schaker TW, Orenstein J, Brenchley J, Fox C, Daucher M, Dewar R, Urban E, Hill B, Guenaga J, Hoover S, Maldarelli F, Hallahan CW, Horn J, **Kottlilil S**, Chun TW, Folino M, Planta MA, Metcalf JA, Douek D, Coffin J, Haase A, Fauci AS and Dybul M. Evaluation of the pathogenesis of declining CD4 T cell counts in HIV-1 infected patients receiving successfully suppressive antiretroviral therapy. *J. Infect Dis.* (2009), 199: 1648-56.
56. Zhang X, Frank AC, Gille CM, Daucher M, Kabat J, Becker S, Lempicki RA, Cortez KJ, Polis MA, Subramanian M, **Kottlilil S.** Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to Mapatumumab-induced apoptosis. *Hepatology Res* (2009), 39:1178-89.
57. **Kottlilil S.**, Reitano KN, Gille CM, Zhang X, Yan M, O'Shea MA, Roby G, Hallahan CW, Yang J, Lempicki RA, Arthos J and Fauci AS. Defective plasmacytoid dendritic cell-NK cell cross-talk in HIV infection. *AIDS Res Hum Retr* (2009), 10: 1029-37.
58. Neumann AU, Goldstein D, Rozenberg L, McLaughlin M, Ferenci P, Masur H, Buti-Ferret M, Fauci AS, Polis MA, and **Kottlilil S.** Hepatitis C viral kinetics during treatment with Peg-IFN-alpha 2b in HIV/HCV co-infected patients as a function of baseline CD4+T cell counts. *JAIDS* (2009), 52:452-8.

59. Rozenberg L., Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, Masur H, Dewar RL, Ferenci P, Silva M, Viola MS, Polis MA and **Kottilil S**. Therapeutic response to Peg-IFN_{alpha-2b} and ribavirin in HIV/HCV co-infected African American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. *AIDS* (2009), 23:2439-50.
60. Cicala C, Martinelli E, McNally J, Goode D, Gopaul R, Hiatt J, **Kottilil S.**, Vann RyK D, Fauci AS, and Arthos J. The Integrin $\alpha 4\beta 7$ Forms a Complex with Cell-Surface CD4 and Defines a T Cell Subset that is Highly Susceptible to Infection by HIV-1. *Proc Natl Acad Sci USA*. (2009), 106:20897-82.
61. Frank AC, **Kottilil S.**, Imamichi T. IL-27 mediated suppression of HCV replication in vitro. *J Interferon and Cytokine Research*. (2010), 30: 427-31.
62. Osinusi A, Rasimas JJ, Bishop R, Proschan M, Murphy AA, McLaughlin M, Polis MA, Masur H, Rosenstein D, **Kottilil S**. HIV/HCV co-infected virologic responders to pegylated interferon and ribavirin therapy more frequently incur IFN-related adverse events than non-responders. *J AIDS* (2010), 53:357-63.
63. Broering R, Trippler M, Jiang M, Zhang X, Lu M, Gerken G, **Kottilil S**, and Schlaak JF. The Interferon stimulated gene 15 is a proviral factor for the Hepatitis C virus and an attenuator of the IFN response. *Gut*. (2010), 59: 1111-9.
64. Asmuth DM, Cai T, Chan E, Murphy RL, Schooley RT, Lertora JL, Rinaldo CR, **Kottilil S**, Wahl S, Thielman N, Li X-D, Lempicki RA, Schreiber M, Shore J, Janik J, Simpson Y, Rosenkranz SL, Cramer Y, Pollard RB for the ACTG A5192 Team. Safety, tolerability and mechanisms of antiretroviral activity of Alpha-alpha 2a in HIV-1 infected subjects: A phase II clinical trial. *J Infect Dis*. (2010), 201: 1686-96.
65. Chary A, Winters MA, **Kottilil S**, Murphy AA, Polis MA, and Holodniy M. Impact of Interferon Ribavirin treatment on Hepatitis C Virus protease quaspecies diversity in HIV/HCV co-infected patients. *J Infect Dis*. (2010), 202: 889-893.
66. Natarajan V, **Kottilil S**, Hazen A, Murphy AA, Adelsberger J, Polis MA and Kovacs JA. HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co-infected individuals. *J Med Virol*. (2010), 82:2032-7.
67. Burbelo PD, Kovacs JA, Ching KH, Issa AT, Iadarola MJ, Murphy AA, Schlaak JF, Masur H, Polis MA and **Kottilil S**. Proteome wide anti-HCV and anti-HIV profiling for predicting and monitoring response to HCV treatment in HIV co-infected patients. *J Infect Dis* (2010), 202:894-8.
68. Moir, S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, Posada, JG, Kardava L, O'Shea MA, **Kottilil S.**, Chu TW, Proschan M, Fauci AS. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. *Blood*. (2010), 116: 5571-9.
69. Murphy AA, Hermann E, Wu L, Sachau W, O'Shea MA, Yang J, Lempicki RA Proschan M, Masur H, Haagmans BL, **Kottilil S** and Polis MA. Twice Weekly Peg IFN-alpha-2a and Ribavirin results in superior viral kinetic response in HIV/HCV Co-infected African American Patients Compared to Standard Treatment. *AIDS* (2011), 25:1179-1187.
70. Burbelo PD, Bren KE, Ching KH, Gogineni ES, **Kottilil S**, Cohen JI, Kovacs J and Iadarola MJ. LIPS arrays for simultaneous detection of antibodies against partial and whole proteomes of HCV, HIV and EBV. *Molecular Biosystems* (2011), 7:1453-62.
71. Sidique N, Shivakumar B, Polis MA, Masur H, **Kottilil S**. Similar Early HCV Kinetics and Therapeutic Response to HCV Therapy among Long Term Non-Progressors and Chronic

- HIV infected Subjects. *J. AIDS* (2011), 58:e38-40.
72. Katsounas A, Trippler M, Wang B, Lempicki RA, Polis MA, **Kottilil S**, Gerken G, Schlaak JF Heat Shock 22kDa Protein 8 (HSPB8) induced Peripheral Toll-like-Receptor (TLR) 4-dependent Immune Activation is associated with Severe Hepatic Fibrosis in Chronic Hepatitis C Virus infection (cHCV). *J Infect Dis* (2011), 8:1181-5.
 73. Shah SR, Patel K, Marcellin P, Foster GR, Manns, M, **Kottilil S**, Healey L, Pulksteni E, Subramanian GM, McHutchison J, Sulkowski M., and Nelson DR. Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Hepatitis C Virus Genotype 3. *Clin Gastro Hepatol* (2011), 9:688-93.
 74. Trehanpati N, **Kottilil S**, Hissar SS, Shrivastava S, Khanam A, Sukriti S, Mishra SK, Sarin SK. J. Circulating Tregs Correlate with Viral Load Reduction in Chronic HBV-Treated Patients with Tenofovir Disoproxil Fumarate. *J. Clin Immunol.* (2011), 31:509-20.
 75. Jones DM, Atoom AM, Zhang X, **Kottilil S**, Russell RS. A Genetic Interaction Between the Core and NS3 Proteins of Hepatitis C Virus is Essential for Production of Infectious Virus. *J Virol.* (2011), 85:12351-61.
 76. Hubbard J, **Kottilil S**. Extra-hepatic replication of the hepatitis C virus: current issues and future directions. *Future Virology* (2011), 6: 275-278.
 77. Hadigan C and **Kottilil S**. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. *JAMA* (2011), 306:294-301.
 78. Rasimas JJ, Katsounas A, Raza H., Rosenstein D, McLaughlin M, Sachau W, O'Shea MA, Masur H, Murphy AA, Lempicki RA, Polis MA, **Kottilil S**. Class Prediction Analyses of Gene Expression Profiles Prior to Treatment Predicts Development of Psychiatric Adverse Events of HCV therapy Among HIV Co-infected individuals *J AIDS* (2012), 60:273-281.
 79. Zhang X, Daucher M, Baeza J, Kim C-W, **Kottilil S**. HIV-1 enhances HCV replication in an HCV continuous culture system expressing CD4 molecule by modulating IFN and TGF-family gene expression. *J. Med Virol* (2012), 84:1344-52.
 80. Katsounas A, Wang B, Trippler M, **Kottilil S**., Lempicki RA, Polis MA, Gerken G, Schlaak JF. CCL5 is a Marker for Early Fibrosis in Chronic Hepatitis C and is regulated by Toll-like receptor 3 signaling and Interferon- α therapy. *J. Vir Hepat* (2012), 19:128-37.
 81. Meissner E, Suffredini A. and **Kottilil S**. Proteomic Profiling of Viral infections. *Future Virology.* (2012), 7:759-65.
 82. Hubbard J, Greenwell-Wild T, Barrett L, Yang J, Lempicki RA, Wahl, SA, Asmuth DA, Murphy RL, Pollard RB, **Kottilil S**. Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with Pegylated interferon-alpha 2a. *J Infect Dis* (2012), 205:1443-7.
 83. Georgoff P, Thomasson D, Louie A, Fleischman E, Dutcher L, Mani H, **Kottilil S**, Morse C, Huang C-Y, Dodd L, Kleiner DE, and Hadigan C. Clinical Utility of 1H Magnetic Resonance Spectroscopy (1H-MRS) for Measurement of Hepatic Steatosis *Am J Radiol* (2012), 99:2-7.
 84. Naggie S, Osinusi A, Katsounas A, Lempicki RA, Herrmann E, Schlaak JF, Shivakumar B, Masur H, Polis MA, **Kottilil S**. Dysregulation Of Host Innate Immunity In HIV/HCV Genotype 1 Infected IL28B CT/TT Haplotype Patients Associated With Depressed Viral Kinetics And Therapeutic Response. *Hepatology* (2012), 56:444-54.
 85. Osinusi A, Naggie S, Herrmann E, Schlaak JF, Shivakumar , Masur H, Polis MA, **Kottilil S**. Effect of ITPA Gene Polymorphisms on the Kinetics of Hemoglobin Declines and HCV

- in HIV/HCV coinfecting subjects *J. Vir Hepat* (2012), 84:1106-14.
86. Katsounas A, Trippler M, **Kottlilil S.**, Lempicki RA, Gerken G, and Schlaak JF. Cytokine/chemokine patterns connect host and viral characteristics with clinics in chronic Hepatitis C infection. *Eur J Med Res.* (2012), 11;17:9.
 87. TrehanPati N, Shrivastava S, Sukriti, Shivakumar B, Kumar B, Bose S, Tripathi DM, Das T, Sakhuja P., Rastogi A, Bihari C, Singh S, Gupta S, **Kottlilil S.**, Sarin SK. Analysis of Notch and TGF- β signaling expression in different stages of disease progression during hepatitis B infection *Clin and Transl. Gastro* (2012), 3:e23.
 88. Kohli A, Zhang X, Murphy AA, Yang J, Donnelly R, Young H, Lempicki RA, **Kottlilil S.** Differential transcriptome profiles and antiviral effect of Interferon- λ and Interferon- α on HCV infected and uninfected hepatoma cells. *J Vir. Hepat.* (2012), 19:843-53.
 89. Osinusi A, Chary A, Winters MA, **Kottlilil S**, Murphy AA, Polis MA, and Holodniy M. IL28B Polymorphism is Not Associated with HCV Protease Diversity in HIV/HCV Co-infected Patients Treated with Pegylated Interferon and Ribavirin *J. Med Virol.* (2012), 10:1522-7.
 90. Kushner LE, Wendelboe AM, Lazerroni LC, Chary A, Winters MA, Osinusi A, **Kottlilil S**, Polis, MA, Holodniy M. Immune Biomarker Differences and Changes in HCV Mono-infected and HIV/HCV Co-infected Patients. *PloS One* (2013), 8(4):e60387.
 91. Shrivasthava S, TrehanPati N, **Kottlilil S**, Sarin SK. Decline in immature transitional B cells following hepatitis B vaccination in HBV positive infants. *Ped Infect Dis.* (2013), 32(7):792-4.
 92. Shrivasthava S, TrehanPati N, Patra S, **Kottlilil S**, Pande C, Trivedi SS, Sarin SK. Increased T regulatory cells and impaired functions of circulating CD8⁺ T lymphocytes is associated with viral persistence in hepatitis B virus positive newborns. *J. Vir Hepat.* (2013), 20(8):582-91.
 93. Sherman AC., TrehanPati N, Brust DG, Formentini E, Daucher M, Davey RT, Masur H, Ghany M, Sarin SK, **Kottlilil S**, and Kohli A. Augmentation of HBV specific cellular immunity with PD-1/PD-L1 blockade in HBV and HIV/HBV patients treated with adefovir. *AIDS Res Hum Retr* (2013), 29(4):665-72.
 94. Katsounas A, Hubbard J, Osinusi A, Wang C, Shivakumar B, Katsounas A, Zhang X, Winter S, Polis MA, **Kottlilil S.** Induction of Interferon stimulating gene (ISG) 15 promotes HCV replication and hinders antiviral activity of Interferon-alpha. *J. Med Virol* (2013), 85(6):959-63.
 95. Zhang X., Daucher M, Armstead D, Russell R, **Kottlilil S.** Identification of Host MicroRNAs that Block HCV Replication in Vitro as Potential Targets for Treatment of HCV. *PLoS One* (2013), 8(2):e55733.
 96. Silver, D, Osinusi, A, Newman, R, Doonquah, L, Henn, S, Teferi, G, Masur, H, **Kottlilil, S.** Fishbein, D. Earlier Staging of Liver Fibrosis in African Americans with HIV-HCV Co-Infection. *Clin. Infect Dis.* (2013), 56(9):1280-3.
 97. Murphy AA, Agarwal C, Shivakumar B, Kohli A. **Kottlilil S.**, Polis MA, Subramanian GM, Sood A, Midha V, Goyals O, Desai SB, Shah SR. Routine HCC Surveillance is Ineffective at Improving Mortality Without Access to HCC Treatment: Results From an Indian Cohort. *Springerplus.* (2014), 17;3:610.
 98. Kohli A, Funk EK, Shivakumar B, Sneller M, Polis MA, Masur H, Heytens L, Nelson A, Kwan R, **Kottlilil S.** Treatment for HCV with Interferon and Ribavirin is Associated with Development of Hypophosphatemia in HIV/HCV Co-Infected Patients. *AIDS Res Hum*

- Retr.* (2013), 29(9):1190-4.
99. Josefson L, Palmer S, Faria NR, Lemey P, Casazza D, Ambrozak D, Kearney M, Shao W, **Kottilil S**, Sneller S, Meller J, Coffin JM, and Maldarelli F. Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T cells contain one HIV-1 DNA molecule. *Plos Pathogens* (2013), 9(6):e1003432.
 100. Cortez KJ, Proschan MA, Barrett L, Brust DG, Formentini E, Davey RT, Masur H, Polis MA, **Kottilil S**. Baseline CD4+ T cell counts predict HBV viral kinetics to adefovir treatment in lamivudine resistant HBV-infected patients with or without HIV infection. *HIV Clin Trials* (2013) 4(4):149-59.
 101. Osinusi A, Meissner EG, Lee Y-J, ; Bon D, Heytens L, Nelson A, Sneller M, M.D. Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan K, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Ph.D, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian GM, McHutchison JG, Polis MA, Fauci AS, Masur H, **Kottilil S**. Sofosbuvir And Ribavirin For Treatment Of Hepatitis C Genotype-1 In Patients With Unfavorable Treatment Characteristics: A Randomized Controlled Trial. *JAMA* (2013) 310:804-11.
 102. Osinusi A, Bon D, Nelson A, Shivakumar B, Lee YJ, Poonia S, Cai, C, Wood BJ, Haagmans BL, Lempicki R, Herrmann E, Sneller M, Polis MA, Masur H, Stanisich E, Chen C, **Kottilil S**. Comparative Efficacy, Pharmacokinetic, Pharmacodynamic Activity and ISG Expression of Different Interferon Formulations in HIV/HCV Genotype-1 Infected Patients. *J Med Virol* (2014), 86(2):177-85.
 103. Sidharthan S, and **Kottilil S**. Mechanisms of Alcohol induced hepatocellular carcinoma. *Hepatology International*. (2014), 8(2):452-457.
 104. Katsounas A, Rasimas JJ, Papadimitriou GN, Polis MA, Gerken G, Schlaak JF, Lempicki RA, Rosenstein DL, **Kottilil S**. The role of ISG20 in Interferon- α induced neuropsychiatric toxicity along with divergent Hepatitis C Virus responses in Human Immunodeficiency Virus positive patients. *J Med Virol* (2014), 86(8):1323-31.
 105. Bon D, Meissner E, Osinusi A., Shivakumar B, Kottilil S, Porkunina L, O'Brien T, and Herrmann E. IFNL4 genotype predicts effectiveness of interferon free antiviral therapy. *J Infect Dis* (2014), 209(11):1700-4.
 106. Lee Y-J, Zhang X, Vazquez E, Siebenlist U, Young H, Shivasabeshan G, Murphy AA, Wang H, Suffredini A, **Kottilil S**. High Levels of Serum IFN α 2a as an Agonist-Antagonist of IFN α Signaling in HIV/HCV Coinfected Subjects. *J Interferon and Cytokine Research*. (2014), 34:28-34.
 107. Osinusi A, Kohli A, Marti MM, Nelson A, Zhang X, Meissner EG, Silk R, Townsend K, Pang PS, Subramanian GM, McHutchison JG, Fauci AS, Masur H, **Kottilil S**. Retreatment of HCV Genotype-1 with Sofosbuvir and Ledipasvir after Relapse with Sofosbuvir and Ribavirin: A Pilot Study. *Annals Intern Med*. (2014), 61(9):634-8.
 108. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, **Kottilil S**. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. *J. Clin Invest* (2014), 124(8):3352-63.
 109. Funk E, **Kottilil S**, Gilliam B, and Talwani R. Selective TLR 7 agonists as antiviral agents for Hepatitis infections. *Curr Trans Med* (2014), 14;12:129.
 110. Kohli A, Sherman A, **Kottilil S**. HCV treatment Paradigms: A Systematic Review. *JAMA* (2014), Aug 13;312(6):631-40.

111. **Kottilil S.** Polis MA and Masur H. Treatment of hepatitis C: When do internists take over? *Annals of Intern Med.* (2014), 161(6):443-4.
112. Kapoor R and **Kottilil S.** Advances in HBV therapeutics. *Future Virology* (2014), 9(6):565-585.
113. Swaminathan S, Sui H, Adelsberger JW, Chen Q, Sneller M, Migueles S, **Kottilil S**, Ober A, Jones S, Rehm CA, Lane HC and Imamichi T. Persistent immune activation in HIV-1 treated patients is associated with a lower level of innate immune responses via cytosolic DNA sensing systems. *J. AIDS & Clin Res.* (2014), 5:315.
114. King TH, Kemmler C, Guo Z, Mann D, Lu Y, Coeshott C, Gehring A, Bertoletti A, Ho Z, Delaney W, Gaggar A, Subramanian GM, McHutchison JG, Shrivastava S, Lee Y-J, **Kottilil S**, Bellgrau D, Rodell T, and Apelian D. A whole recombinant yeast-based therapeutic vaccine elicits hbv x, s and core specific t cells in mice and induces ex vivo expansion of t cells that recognize epitopes associated with viral clearance. *PLoS ONE* (2014), Jul 22;9(7):e101904. doi: 10.1371/j.
115. Meissner EG, Nelson A, Marti MM, Masur H, Osinusi A, **Kottilil S** Sustained Virologic Response for Chronic Hepatitis C Infection after 27 days of Treatment with Sofosbuvir and Ribavirin. *Open For Infec Dis* (2014), 1 (1): 013.
116. Kim C-W, Sidharthan S, Heytens L, Murphy A, Sneller MC, **Kottilil S.** Differential Gene expression profiles of PBMCs in mixed cryoglobulinemic vasculitis patients. *Frontiers in immunology* (2014), May 27;5:248.
117. Osinusi A, Odigie M, Zhang X, Imamichi T, Barrett L, Polis MA, Masur H, **Kottilil S.** IL23 promotes interferon alpha responsiveness in HIV/HCV coinfecting subjects treated with pegylated interferon and ribavirin *AIDS Hum Retr* (2014), Aug;30(8):775-82.
118. Shaffer A., Hubbard J, Barrett L, Kohli A, **Kottilil S.** A highly predictive assay to detect single nucleotide polymorphisms using serum from HIV-infected subjects. *AIDS Res Hum Retro* (2014), Aug;30(8):792.
119. Narayanan S. Osinusi A., Talwani R, Funk E., **Kottilil S.** Favorable Adverse Event Profile Of Sofosbuvir/Ribavirin Compared To Boceprevir/Interferon/Ribavirin For Treatment Of Hepatitis C *Hepat International* (2014), Oct;8(4):560-6.
120. Meissner E, Osinusi A, Naggie S. Patel K, McHutchison J, Symonds W, Polis MA, Masur H, and **Kottilil S.** Effect of sofosbuvir and ribavirin on peripheral and hepatic lipid metabolism in chronic hepatitis C genotype 1 patients. *Hepatology* (2014), Mar;61(3):790-801.
121. Kohli A and **Kottilil S.** Assessment of outcomes of Hepatitis C Treatment. *JAMA* (2014), Dec 17;312(23):2571.
122. Barrett L. Trehanpati N, Poonia S, **Kottilil S.** Hepatic compartmentalization of exhausted regulatory cells in chronic hepatitis C patients. *J Vir Hepatitis* (2015), Mar;22(3):281-8.
123. Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, M.S., Marti MM, Silk R, Kotb C, Gross C, Jolley T, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, M.D. Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, **Kottilil S.** Directly Acting Triple Drug Anti-HCV Therapy Induces Complete Virologic Response with a Six Week Regimen: A Proof-of-Concept Phase 2a Cohort Study. *Lancet* (2015), Mar 21;385(9973):1107-13.
124. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R,

- Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H and **Kottilil S**. A Pilot Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in HCV Genotype 1 Subjects Coinfected with HIV Infection. *JAMA* (2015), Mar 24-31;313(12):1232-9.
125. Cortez KJ and **Kottilil S**. Beyond interferon: rationale and prospects for newer treatments in chronic hepatitis C infection. *Therapeutic Advances in Chronic Diseases*. (2015), 6(1):4-14.
 126. Kohli A, Funk E, Burbelo P, Barrett L, Meissner EG, Santich B, Shaffer A, Johl J, Sidharthan S, Moir S, **Kottilil S**, Fauci AS. Persistently Elevated Abnormal B-cell Subpopulations & Anti-core Antibodies in HIV/HCV Co-infected Patients Who Relapse. *J Med Virol* (2015), Apr;87(4):544-52.
 127. Kattakuzhy S, and **Kottilil S**. Sofosbuvir for Treatment of Chronic Hepatitis C. *Hepatology International* (2015), Apr;9(2):161-73.
 128. Katsounas A, Frank AC, Lempicki RA, Polis MA, Asmuth D, **Kottilil S**. Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo. *Journal of AIDS Clin Research* (2015), 6(1). pii: 1000410.
 129. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, **Kottilil S**. Virologic response to sofosbuvir and ledipasvir in HIV/HCV coinfecting patients *JAMA* (2015), 14;314(2):186-7.
 130. Sidharthan S, Kohli A, Sims Z, Nelson A, Osinusi A, Masur H, and **Kottilil S**. Utility of HCV VL monitoring on Directly Acting Antiviral Therapy. *Clin Infect Dis* (2015), Jun 15;60(12):1743-51.
 131. Gane EJ, Lim YS, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, Roberts S, Massetto B, Ye Z, Pflanz S, Garrison KL, Gaggar A, Mani Subramanian G, McHutchison JG, **Kottilil S**, Freilich B, Coffin CS, Cheng W, Kim YJ. The Oral Toll Like Receptor-7 Agonist GS-9620 in patients with Chronic Hepatitis B Infection. *J Hepatology* (2015), Aug;63(2):320-8.
 132. Sidharthan S, Kohli A and **Kottilil S**. Reply to Harrington et al. *Clin Infect Dis* (2015), Aug 15;61(4):667-8.
 133. **Kottilil S**, Wright M, Polis MA, Masur H, Treatment for Hepatitis C infection. *Annals of Intern Med*. (2015), Mar 17;162(6):459.
 134. Rower J, Meissner E, Jimmerson L, Osinusi A, Sims Z, Petersen T, Bushman L, Wolfe P, McHutchison JG, **Kottilil S**, Kiser J. Serum and Cellular Ribavirin Pharmacokinetic and Concentration-Effect Analysis in HCV Patients Receiving Sofosbuvir plus Ribavirin. *J Antimicro Chemotherapy* (2015) Aug;70(8):2322-9.
 135. Kattakuzhy S, Levy R, and **Kottilil S**. Sofosbuvir for treatment of chronic hepatitis C. *Hepatology International* (2015), Apr;9(2):161-73.
 136. Kohli A., Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang P, Osinusi A, Polis MA, Rustgi V, Masur H and **Kottilil S**. Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof-of-Concept Phase 2a Cohort Study. *Lancet Infect Dis* (2015), Sep;15(9):1049-54.

137. AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus. *Hepatology* (2015), Sep;62(3):932-54.
138. Meissner EG, Decalf J, Casrouge A, Masur H, **Kottilil S**, Albert ML, Duffy D. Dynamic Changes of Post-translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-free Therapy. *PLOS ONE* (2015), Jul 16;10(7):e0133236.
139. Tang L and **Kottilil S**. Treatment of HCV in HIV-infected patients: no longer a challenge? *The Lancet HIV* (2015), 2(8): e308-9
140. Heill E, Hynicka LM, **Kottilil S**, Tang L. What does the pharmacological future of treating chronic hepatitis C look like? *Expert Reviews in Pharmacology* (2015), Sep;8(5):605-22.
141. Tang L, Ward H, Kattakuzhy S, Wilson E, **Kottilil S**. Dual Sofosbuvir and ribavirin therapy for hepatitis C infection. *Expert Rev in Gastro Hepatol.* (2015), 10(1):21-36.
142. Kohli, A, Kattakuzhy S., Sidharthan S., Nelson A, McLaughlin M., Seamon C, Wilson E, Meissner EG, Sims Z, Silk R.; Gross C, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M.; Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, **Kottilil S**. Four-week Directly Acting Anti-HCV Regimens in HCV Genotype-1 Patients without Cirrhosis: A Phase 2a Cohort Study. *Annals of Intern Med* (2015), 163(12):899-907.
143. Hahn K, Kohli A, Sims Z, **Kottilil S**. Durable Sustained Virologic Response after oral directly acting antiviral therapy despite immunosuppressive treatment. *Open Forum Infect Dis* (2015), 2(3):ofv091.
144. Sehgal R, Patra S, David P, Vyas A, Khanam A, Hissar S, Chibber G, **Kottilil S**, Maiwall R, Sarin SK, Trehanpati N. Impaired monocyte and macrophage functions and defective TLR signaling in hepatitis E virus infected pregnant women with acute liver failure. *Hepatology* (2015), doi: 10.1002/hep.28143.
145. Townsend K, Petersen T, Gordon LA, Kohli A, Nelson A, Seamon C, Gross C, Tang L, Osinusi A, Polis MA, Masur H, **Kottilil S**. Effect of HIV co-infection on adherence to a 12-week regimen of regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. *AIDS* (2015), 30(2):261-6.
146. Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, Gross C, Calderon M, Proschan M, Osinusi A, Polis MA, Masur H, **Kottilil S**, and Kohli A. High adherence to directly acting antiviral therapy in inner city HCV infected patients. *Hepatol International* (2015), 10(2):310-9.
147. Townsend K, Meissner EG, Sidharthan S, Sampson M, Remaley A, Kohli A, Osinusi A, Masur H and **Kottilil S**. Interferon free of HCV in HIV infected subjects results in increased serum LDL levels. *Aids Hum Retr* (2015), 32(5):456-62.
148. Wilson EM, Kattakuzhy S, Sidharathan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A and **Kottilil S**. Successful retreatment of chronic hepatitis C genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct acting antiviral regimens. *The Clin Infect Dis*, (2015) ;62(3):280-8.
149. Meissner EG, Kohli A, Virtaneva K, Sturdevant D, Martens C, Porcella SF, McHutchison JG, Masur H, **Kottilil S**. Favorable response to HCV treatment with directly acting antivirals correlates with changes in hepatic interferon gene expression independent of cirrhosis. (2015), *J Vir Hep* 23(7):496-505.

150. Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, **Kottilil S**. Six-week Combination Directly Acting Anti-HCV Therapy Induces Moderate Rates of Sustained Virologic Response in Patients with Advanced Liver Disease. *Clin Infect Dis*. (2015), 62(4):440-7.
151. O'Brien TR, Feld JJ, **Kottilil S**, Pfeiffer RM. No scientific basis to restrict 8 weeks of treatment with Ledipasvir/Sofosbuvir to patients with HCV RNA <6,000,000 IU/ml. *Hepatology* (2015) 63(1):28-30
152. Bagchi S, Patel P, Faramand R, Burrowes S, Hossain MB, **Kottilil S**, Miller M, Fantry LE, Redfield RR. Underutilization of Statins for Prevention of Cardiovascular Disease Among HIV-Infected Patients. *J AIDS Clin Res* (2015) 6:9. <http://dx.doi.org/10.4172/2155-6113.1000499>.
153. Wilson EM and **Kottilil S**. Eradication strategies for HBV. *Clin Infect Dis* (supplement) (2016), Jun 1;62 Suppl 4:S318-25.
154. Shrivastava S, Meissner EG, Funk E, Poonia S, Shokeen V, Thakur A, **Kottilil S**, Sarin SK, Trehanpati N. Elevated hepatic lipid and interferon stimulated gene expression in patients infected with hepatitis C virus genotype-3 relative to patients with non-alcoholic steatohepatitis (NASH). *Hepatol Intern* (2016), 10(6):937-94.
155. Ward H, Tang L, Poonia B, **Kottilil S**. Treatment of HBV: an update. *Future Microbiology* (2016), 11:1581-1597.
156. Petersen T, Lee YJ, Osinusi A, Amorosa V, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, **Kottilil S** and Peters MG. Interferon Stimulated Gene Expression in HIV/HCV Co-infected Patients treated with Nitazoxanide/ Peginterferon Alfa-2a and Ribavirin *AIDS Res Hum Retr* (2016), 32(7):660-7.
157. Rosenthal E, Polis MA, **Kottilil S**. Sofosbuvir and Ledipasvir for HIV/HCV Coinfection. *Exp Opin on Pharmacotherapy* (2016) 17(5):743-9.
158. Papudesu C and **Kottilil S**, Bagchi S. Grazoprevir-Elbasvir for treatment of HCV Infection *Hepatol. Intern* (2016) 11(2):152-160.
159. Poonia B and **Kottilil S**. Newer therapeutics for hepatitis C *Annals Transl Med* (2016) 4(2):31.
160. Mathur P, **Kottilil S**., Husson J. Management of hepatitis C infection in patients with End Stage Renal Disease. *Curr Top Infect Dis* (2016). 8(4): 438-448
161. Tang L, Marcell L, **Kottilil S**. Systemic manifestations of hepatitis C infection. *Infections and Cancer* (2016) May 23;11:29.
162. Bean M, Tang L, **Kottilil S**, Beavers KL, Meissner EG. On treatment elevations in hepatic transaminases during HCV treatment with ombitasvir, paritaprevir and dasabuvir. *Case Rep Infect Dis Open forum for Infect Dis* (2016) 2016:6151570 .
163. Jimmerson LC, Urban TJ, Truesdale A, Baouchi-Mokrane F, **Kottilil S**, Meissner EG, Sims Z, Hodara A, Aquilante, CL, Kiser JJ. Variant ITPA Phenotypes are Associated with Increased Ribavirin Triphosphate Levels. *J Clin Pharm* (2016) Jun 28. doi: 10.1002/jcph.783.
164. Emmanuel B, Shardell MD, Tracy L, **Kottilil S**, El-Kamary SS. Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III. *J Viral Hepat*. (2016) Dec 1.

165. Tang L, Masur J, Sims, Z Nelson A, Osinusi A, Kohli A, Kattakuzhy, S, Polis M, and **Kottilil S**. Safe and Effective Sofosbuvir-based Therapy in Patients with Mental Health Disease on Hepatitis C Treatment. *W. J Hepatology* (2016) 8(31):1318-1326.
166. Burrowes S, Cahill P, **Kottilil S** and Bagchi S, Contribution of Antiretroviral Therapy to Cardiovascular Disease Risk in HIV-Infected Patients *Future Virology* (2016) 11(7): 509–527.
167. Chua J, and **Kottilil S**. Sofosbuvir and Velpatasvir: A stellar option for Patients With Decompensated Cirrhosis. *Annals of Translational Medicine* (2016) S8: 48
168. Lee R, Wilson E, **Kottilil S**. Eradication Strategies for chronic Hepatitis B. *ID Practitioner* 2016, August 24, 2016.
169. Meissner EG, McLaughlin M, Matthews L, Gharib AM, Wood BJ, Levy E, Sinkus R, Virtaneva K, Sturdevant D, Martens C, Porcella SF, Goodman ZD, Kanwar B, Myers RP, Subramanian M, Hadigan C, Masur H, Kleiner DE, Heller T, **Kottilil S**, Kovacs JA, Morse CG. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. *Liver Int.* (2016) May 27.
170. Emmanuel B, Sidique N, Zhang X, Poonia B, Sneller MC, **Kottilil S**, Decline in Cellular Activation in non-B cells after Rituximab Treatment in Hepatitis C-Associated Mixed Cryoglobulinemia Vasculitis *J Vir Hepatitis* (2017), 24(2):128-131.
171. Wilson E, Rosenthal E, Kattakuzhy S, Tang L, **Kottilil S**. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C *Clin Microbiol Rev* (2017) 30(1):23-42.
172. Lee R, Wilson E, **Kottilil S**. Sofosbuvir/velpatasvir: A Pan genotypic Drug to Simplify HCV therapy *Hepatol. Intern.* 2017 (2):161-170.
173. Jimmerson L, Clayton C, MaWhinney S, Meissner EG, Sims Z, **Kottilil S**, Kiser J. Effects of Ribavirin/Sofosbuvir/Treatment and ITPA phenotype on endogenous purines. *Antiviral Research.* 2017 138:79-85.
174. O'Brien TR, **Kottilil S**, Feld JJ, Pfeiffer RM. Race or Genetic Makeup for HCV Treatment Decisions? *Hepatology* (2017) Jun;65(6):2124-2125
175. Trehanpati N, **Kottilil S**, Patra S, Vasudevan M, Shgal R, David P, Vyas A, Khosla R, Khanam A, Kumar G, Hissar S, Ramakrishna G, Sarin SK. miRNA Signatures indicate Acute Liver Failure in hepatitis E infected pregnant females. *Heliyon* 2017 Apr 6;3(4):e00287. doi: 10.1016
176. Wyles D, Brau N, **Kottilil S**, Daar E, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Doehle B, Huang KC, Osinusi A, McNally J, Brainard D, McHutchison JG, Naggie S, Sulkowski M. for the ASTRAL-5 investigators. Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study. *Clin Infect Dis.* 2017 Jul 1;65(1):6-12.
177. Shrivastava S, Wilson, E, Poonia, B, Tang L, Osinusi A, Kohli A, **Kottilil, S**. Augmentation of HCV specific immunity and SVR. *J. V Hepat.* (2017) Sep;24(9):742-749.
178. Gharib AM, Thanda Han MA, , 7E, Kleiner DE, Zhao X, McLaughlin M, Matthews L, Rizvi B, Abd-Elmoniem K-Z, Sinkus R, Levy E, Koh C, Myers RP, Subramanian GM, **Kottilil S**, Heller T, Kovacs J and Morse C. Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. *Biomed Res International* 2017;2017:2067479.
179. Chua JV, **Kottilil S**. Are we nearing the end in the fight against hepatitis C? *Expert Rev Gastroenterol Hepatol.* (2017) Jun;11(6):499-500.

180. Nguyen T, Guedj J, Uprichard S, Kohli A, **Kottlilil S** and Perelson A. The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics. *Sci Reports* 2017 Aug 31;7(1):10233
181. Emmanuel B, Wilson EM, O'Brien T, **Kottlilil S**, Lau G. Shortening the duration of therapy for chronic hepatitis C infection. *The Lancet Gastro & Hepatol* 2017 Nov;2(11):832-836. doi: 10.1016/S2468-1253(17)30053-5
182. Meissner EG, Kohli A, Higgins J, Lee Y-J, Prokunina O, Wu D, Orr C, Masur H and **Kottlilil S**. Rapid Changes in Peripheral Lymphocyte Concentrations During Interferon-free Treatment of Chronic HCV Infection. *Hepitol Comm* (2017) Sep;1(7):586-594.
183. Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, **Kottlilil S**; and the ASCEND Providers. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. *Ann Intern Med* (2017) Sep 5;167(5):311-318
184. Mathur P, Comstock E, McSweegan E, Mercer N, Kumar NS, **Kottlilil S**. A pilot study to expand treatment of chronic hepatitis C in resource-limited settings. *Antiviral Research*, 2017 Oct;146:184-190. doi: 10.1016
185. Younossi Z, Stepanova M, Sulkowski M, Wyles D, **Kottlilil S**, Hunt S. The Sofosbuvir and Velpatasvir Regimen is Associated with High Efficacy and Improvement of Patient-Reported Outcomes in Patients Co-infected with Hepatitis C and Human Immunodeficiency Virus: The Data from ASTRAL-5 Study. *Liver International*. 2018, 37(12):1796-1804
186. Abutaleb A, and **Kottlilil S**. Vedoprevir in the Management of Hepatitis C Infection. *Exp Opin on Invest Drugs* 2017 Dec;26(12):1399-1402
187. O'Brien TR, **Kottlilil S**, Pfeiffer RM. *IFNL4* Genotype is Associated with Relapse for 8-Week Treatment with Sofosbuvir, Velpatasvir and Voxilaprevir. *Gastroenterology* 2017 Dec;153(6):1694-1695. doi: 10.1053
188. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Ledinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. *N Engl J Med*. 2017 Jun 1;376(22):2134-2146.
189. Bagchi S, Burrowes S, Fantry LE, Hossain MB, Tollera GH, **Kottlilil S**, Pauza D, Miller M, Baumgarten M, Redfield RR. Factors Associated with High Cardiovascular Risk in a Primarily African-American, Urban HIV-Infected Population *SAGE Open Med*. 2017 Aug 10;5:2050312117725644
190. Husson J, Ravichandran B, Joncche S, **Kottlilil S**. and Wilson E. Eight weeks of ledipasvir/sofosbuvir in Kidney transplant recipients with hepatitis C genotype 1 infection. *Transplantation Direct* 2017 Nov 3;3(12):e229
191. Chaudhury C, Sheehan J, Chairez C, Akoth E, Gross C, Silk R, Kattakuzhy, Rosenthal, **Kottlilil S**, Masur H, and Hadigan C. No Improvement in Hemoglobin A1c following Hepatitis C Viral Clearance in Patients with and without HIV Co-infection. *J. Infect Dis* (2017) Dec 27;217(1):47-50

192. Comstock E, Kim C-W, Murphy AA, Emmanuel B, Zhang X, Sneller MC, Poonia B and **Kottlilil S**. Transcriptional profiling of PBMCS unravels B cell mediated immunologic imprints in HCV vasculitis. *PLoS ONE*. 2017, 12(12):e0188314.
193. Price A, Gross C, Akoth E, Wilson E, Osinusi A. and **Kottlilil S**. Supervised ART interruption to allow HCV therapy with DAAs in HIV/HCV coinfecting subjects *Virology Research Journal* (2017), 1:17-20.
194. Redden AD, Hynicka LM, Chua JV and **Kottlilil S**. Treatment of hepatitis C in HIV infected patients. *Internal Medicine reviews* (2017) doi:10.18103/imr.v3i12.588.
195. Tang L, Parker A, Flores Y, Dellario M, Dockson C, Amoroso A, **Kottlilil S**. and Wilson E. Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population. *J. Vir Hep* 2018 Feb;25(2):205-208.
196. Tang L, Covert E, Wilson E, **Kottlilil S**. Treatment of Hepatitis B infection: A Systematic Review. *JAMA* 2018 May 1;319(17):1802-1813
197. Abutaleb A, Kottlilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. (2018) *Hepatol Intern*. May;12(3):214-222
198. Mee T, Chaudhury C, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, **Kottlilil S**, Masur H, Stanley T, Hadigan C Testosterone in Men with Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance. *Clin Infect Dis* (2018) doi: 10.1093
199. Mathur P, **Kottlilil S**, Tang L. Use of ribavirin for hepatitis C treatment in the modern era of DAAs. *J. Clin Trans Hepatol*. (2018), 6(4):431-437
200. Abutaleb A, Kattakuzhy S, **Kottlilil S**, Wilson E. Mechanisms of neuropathogenesis in HIV and HCV: similarities, differences, and unknowns. *Journal of Neuro Virology* (2018), 6):670-678
201. Rosenthal E, Kattakuzhy S and **Kottlilil S**. Time to End Treatment Restrictions for People With Hepatitis Who Inject drugs. *Lancet Gastroenterol Hepatol* (2018) Mar;3(3):142-143
202. Mathur P, Emmanuel B, Sneller MC, Zhang X, and Poonia B, **Kottlilil S**. Recovery of Hepatitis C-Specific T cell response after Rituximab therapy in hepatitis C Mixed Cryoglobulinemic vasculitis. *J Med Virol* (2018) May;90(5):936-941.
203. Naggie S, Clement M, Lusk S, Osinusi A, Himmel T, Lucas JE, Thompson WJ, Dubois L, Moseley MA, Clark PJ, **Kottlilil S**, Patel K. Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. *Proteomics Clin Appl*. 2018 Jul 30:e1800006.
204. **Kottlilil S**. Shortening Treatment for Hepatitis C Virus Infection. *Gastroenterol Hepatol* (N Y). 2018 Mar;14(3):186-188.
205. Orr C, Aartun J, Masur H, **Kottlilil S**, Meissner EG. Characterization of Changes in Intrahepatic Immune Cell Populations During HCV Treatment with Sofosbuvir and Ribavirin. *J Vir Hep* 2019, 26(3):323-328
206. Mathur P, Comstock E, Makuza JD, Emmanuel B, Sebeza J, Kiromera A, Wilson E, Kattakuzhy S, Nelson A, **Kottlilil S**, Riedel DJ. Implementation of a unique hepatitis C care continuum model in Rwanda. *J Public Health (Oxf)*. (2018), 41(2)e203-208.
207. Shah ASV, Stezle D, Lee KK, Beck EJ, Alam S, Clifford S, Longenecker C, Strachan F, Bagchi S, Whiteley W, Rajagopalan S, **Kottlilil S**, Newby DE, Nair H, McAllister DA, Mills NL. Global burden of cardiovascular disease in people living with human immunodeficiency virus. *Circulation* (2018), 138(11):1100-1112

208. Emmanuel B, Masur H, **Kottlilil S**, Kattakuzhy S. Expansion of Treatment for Hepatitis C Virus Infection. *Ann Intern Med*. 2018 Mar 20;168(6):457-459.
209. Mathur P, **Kottlilil S**. and Wilson E. Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult to treat patients. *Antiviral Ther* (2019), 24: 1-10.
210. Narayanan S., Abutaleb A, Sherman KE, **Kottlilil S**. and Sherman KE. Clinical features and determinants of Chronicity in Hepatitis E virus Infection. *J. Vir Hep*. (2019), 26(4):414-421
211. Tang L, **Kottlilil S**. Treatment of hepatitis B infection: A reply. *JAMA* 2018, 18;320(11):1202
212. Shrivastava S, Bhatta M, Ward H, Romani S, Covert E, Rosenthal E, **Kottlilil S**, and Wilson E. Multi-target DAA therapy is associated with superior Immunological recovery in HIV/HCV Coinfected patients” *Hep Comm*. 2018, 2(12):1451-1466
213. Sherman KE, Abdel-Hameed E, Rouster SD, Shata MT, Blackard JT, Safaie P, Kroner B, Preiss L, Horn L, **Kottlilil S**. Improvement in hepatic fibrosis biomarkers associated with CCR5 inactivation through mutation or therapeutic blockade. *Clin Infect Dis* (2018), 68: 1911-1918.
214. Poonia B, Ayithan N, Nandi M, Masur, H and **Kottlilil S** (2018). HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis. *Nature Sci Rep* 2018, 8(1):15296
215. Tang L, Kamat M, Shukla A, Vora M, Kalal CR, **Kottlilil S**, and Shah S. Comparative Antiviral Efficacy of Generic Sofosbuvir versus SOVALDI with ribavirin for the treatment of Hepatitis C *Interdisciplinary Perspectives in Infectious Diseases* (2018) doi: 10.1155/2018/9124604
216. Wilson E, **Kottlilil S** and Poonia B. "Can directly acting antiviral regimens against hepatitis C induce host immune responses’ *Future Virology* (2018) 13: 147-50.
217. Mattingly JT, Onukwugha E, Perfetto EM, **Kottlilil S**, Mullins D. What matters most for treatment decisions in hepatitis C: Effectiveness, costs and altruism. *Patient* (2019), 12: 631-638.
218. Emmanuel B, El-Kamary S, Charurat M, Madger L, Hadigan C, **Kottlilil S**. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and negative chronic hepatitis C patients. *Hep Intern* (2019) 3: 270-6.
219. Ghosh A, Mondal R, Romani S, Bagchi S, Cairo C, Pauza CD, **Kottlilil S**, Poonia B. Persistent Gamma-Delta T cell dysfunction in chronic HCV infection despite direct-acting antiviral therapy induced cure *J Vir Hep* (2019) 10:1835.
220. Jakharia N, **Kottlilil S**, Chua J. Role of HBsAg quantitation in HIV/HBV patients: A review. *AIDS Review* (2019) 21: 175-83.
221. Balmaceda JB, Aepfelbacher J, Belliveau O, Chaudhury CS, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, **Kottlilil S**, Kleiner DE, Hadigan C. Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV. *Antiviral Ther* (2019), 24: 451-7.
222. Wilson E, Covert E, Hoffmann J, Comstock E, Emmanuel B, Tang L, Husson J, Chua J, Price A, Mathur P, Rosenthal E, Kattakuzhy S, Masur H, **Kottlilil S**. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). *J. Hepatology* (2019), 71: 498-504.
223. Blackard JT, Kong L, Rouster SD, Karns R, Horn PS, **Kottlilil S**, Shata MT, Sherman KE.

- CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro. *PLoS One* (2019), 14: e0224523.
224. Romani S, Stafford K, Bagchi S, **Kottilil S**, Poonia B. Peripheral PD-1+ T cells co-expressing inhibitory receptors predict SVR with ultra-short duration DAA therapy in HCV infection *Frontiers in Immunology*. (2019), 27: 1451-1466.
 225. Hyun J, McMahon RS, Lang AL, Edwards JS, Badilla AD, Greene ME, Stone GW, Pallikkuth S, Stevenson M, Dykxhoorn DM, **Kottilil S**, Pahwa S, Thomas E. HIV and HCV augments inflammatory responses through increased TREM-1 expression and signaling in Kupffer and Myeloid cells. *PLoS Pathog* (2019), 15:e1007883.
 226. Mathur P and **Kottilil S**. Hepatitis core antigen testing: Still an effective diagnostic method for global elimination of hepatitis C? *Clin Infect Dis* (2020), 70: 674-5.
 227. Abutaleb A and **Kottilil S**. Hepatitis A: Epidemiology, Natural History, Unusual Manifestations and Prevention. *Gastro Clinics of N. America*. (2020), 49: 191-9.
 228. Tang L, Wilson E, and **Kottilil S**. Strategies to eliminate HBV infection; an update *Future Microbiology* (2020) 15: 35-51.
 229. Perdomo-Celis F, Medina-Moreno S, Davis H, Bryant J, Taborda NA, Rugeles MT, **Kottilil S**, Zapata JC. Characterization of CXCR5+ T-cells in humanized NSG mice: a model to explore their dynamic during HIV infection. *Immunobiology*. (2020) 225: 151885.
 230. Perdomo-Celis F, Medina-Moreno S, Davis H, Bryant J, Taborda NA, Rugeles MT, **Kottilil S**, Zapata JC. High activation and skewed T cell differentiation are associated with low IL-17A levels in a hu-PBL-NSG-SGM3 mouse model for HIV infection. *Clin Exp Immunol*. (2020) 200: 185-198.
 231. Mattingly JT, Onukwugha E, Perfetto EM, **Kottilil S**, Mullins D. Value in hepatitis C virus treatment: A patient-centered cost-effectiveness analysis. *Pharmacoeconomics*. (2020), 38: 233-242.
 232. Rosenthal E, Silk R, Mathur P, Gross C, Eyasu R, Nussdorf L, Hill K, Brokus C, D'Amore A, Sidique N, Bujole P, Jones M, Kier R, McCullough D, Sternberg D, Stafford K, Sun J, Masur H, Kattakuzhy S and **Kottilil S**. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs *Clin Infect Dis* (2020) doi: 10.1093/cid/ciaa105.
 233. Emmanuel B, El-Kamary S, Madger LS, Stafford KA, Charurat ME, Chairez C, McLaughlin M, Hadigan C, Porkunina-Olsson L, O'Brien TR and **Kottilil S**. Metabolic changes in chronic hepatitis C patients who carry IFNL4-G and achieve sustained virologic response with direct acting antiviral therapy *J. Infect Dis* (2020) 221: 102-9.
 234. Gindin Y, Gaggar A, Lok A, Janssen HL, Ferrari C, Subramanian M, Jiang Z, Masur H, Emmanuel B, Poonia B and **Kottilil S**. Age acceleration associated with inflammatory response in chronic hepatitis B and C patients predicted using a novel immune clock. *Clin Infect Dis* (2020) doi: 10.1093/cid/ciaa1371
 235. Abutaleb A, Khatun M, Clement J, Baidya A, Singh P, Datta S, Ahammed AM, Koshy G, Mukherjee PS, Santra A, Neogi S, Parikh S, Pillai V, **Kottilil S**, Chowdhury A. A novel model of care optimized for marginalized remote population unravels novel migration pattern in India *Hepatology* (2020) doi: 10.1002/hep.31461.
 236. Poonia B and **Kottilil S**. Immunecorrelates of COVID-19 control. *Front Immunol* (2020) 10.3389/fimmu.2020.569611
 237. Chumakov C, Benn CS, Aaby P, **Kottilil S**. and Gallo RC. Can existing vaccines prevent COVID-19? *Science* (2020) 368: 1187-8.

238. Rikhtegaran Tehrani Z, Saadat S, Saleh E, Ouyang X, Constantine N, DeVico AL, Harris AD, Lewis GK, **Kottlilil S**, Sajadi MM. Specificity and performance of nucleocapsid and spike-based SARS CoV2 serologic assays *medRxiv* (2020), doi: 10.1101/2020.08.05.20168476
239. Kim JH, Ghosh A, Ayithan N, Romani S, Khanam A, Park JJ, Rijnbrand R, Tang L, Sofia MJ, **Kottlilil S**, Moore CB, Poonia B. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients. *Sci Rep* (2020), 10: 1835-90.
240. Bunn HT, Rosenthal E, Mathur P, McLaughlin M, Proschan M, Vijan A, Aepfelbacher J, **Kottlilil S**, Masur H, Kattakuzhy S, George JM. The effect of GS-548351 on the pharmacokinetics of midazolam following multiple doses ANS-6637 in healthy adults. *J Clin Pharmacol.* (2020), doi: 10.1002/jcph.1672
241. Abdel-Hameed EA, Rouster SD, **Kottlilil S**, Sherman KE. The enhanced liver fibrosis (ELF)-index predicts hepatic fibrosis superior to FIB4 and APRI in HIV/HCV infected patients. *Clin Infect Dis* (2021), doi: 10.1093/cid/ciaa646.
242. Reyes M, Lutz JD, Lau AH, Gaggar A, Grant EP, Joshi A, Mackman RL, Ling J, Tan SK, Ayithan N, Daffis S, Woo J, Wu P, Lam T, Fletcher SP, **Kottlilil S**, Poonia B, Gane EJ, Mathias A, German P. Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor-8 agonist: a phase 1a study in healthy subjects. *Antiviral Ther* (2020), doi: 10.3851/IMP3363.
243. Hauser N, Gushiken AC, Narayanan S, **Kottlilil S**. and Chua J. Evolution of Nipah Virus Infection: Past, Present and future Considerations. *Trp Med Infect Dis* 202, 6: 24.
244. Hill K, Nussdorf L, Mount JD, Silk R, Gross C, Sternberg D, Bijole P, Jones M, Kier R, McCullough D, Mathur P, **Kottlilil S**, Masur H, Kattakuzhy S, Rosenthal ES. Initiation of low threshold buprenorphine in nontreatment seeking patients with opioid use disorder engaged in hepatitis C treatment. *J. Addict Med* 2022, 16:10-17.
245. Polaris Observatory Collaborators. The case for simplifying and using absolute targets for viral hepatitis elimination goals. *J Viral Hepat.* 2021 Jan;28(1):12-19. doi: 10.1111/jvh.13412.
246. Dugan E, Blach S, Biondi M, Cai Z, DePaola M, Estes C, Feld J, Gamkrelidze I, **Kottlilil S**, Ma S, Mathur P, Montoya S, Razavi-Shearer D, Razavi-Shearer K, Robbins-Scott S, Schmelzer J, Razavi H. Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. *Lancet Gastroenterol Hepatol.* 2021 Mar;6(3):169-184.
247. Khanam A, Ayithan N, Tang L, Poonia B, **Kottlilil S**. IL-21-Deficient T Follicular Helper Cells Support B Cell Responses Through IL-27 in Patients With Chronic Hepatitis B. *Front Immunol.* 2021 11:599648.
248. Soriano V, Barreiro P, Cachay E, **Kottlilil S**, Fernandez-Montero JV, de Mendoza C. Advances in hepatitis B therapeutics. *Ther Adv Infect Dis.* 2020 7:2049936120965027.
249. Khalsa JH, Bunt G, Maggirwar SB, **Kottlilil S**. COVID-19 and Cannabidiol (CBD). *J Addict Med.* 2020 doi: 10.1097/ADM.0000000000000771
250. Rikhtegaran Tehrani Z, Saadat S, Saleh E, Ouyang X, Constantine N, DeVico AL, Harris AD, Lewis GK, **Kottlilil S**, Sajadi MM. Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays. *PLoS One.* 2020 Nov 2;15(11):e0237828.
251. Ghosh A, Romani S, **Kottlilil S**, Poonia B. Lymphocyte Landscape after Chronic *Hepatitis C Virus* (HCV) Cure: The New Normal. *Int J Mol Sci.* 2020 Oct 10;21(20):7473. doi: 10.3390/ijms21207473.

252. Agrawal T, Gaggar A, Subramanian M, **Kottlilil S**, Choudhary A, Rao PN, Shah S, Trehanpati N. PNPLA3 polymorphisms are associated with raised alanine aminotransferase levels in hepatitis C virus genotype 3. *Arab J Gastroenterol*. 2020 (4):267-272.
253. Chua JV, Ntem-Mensah A, Abutaleb A, Husson J, Mutumbi L, Lam KW, Ghosh A, Romani S, Poonia B, Lee S, Luz Pascual M, Frumkin LR, **Kottlilil S**. Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study. *J Med Virol*. 2020 Nov 5. doi: 10.1002/jmv.26652.
254. Peters MG, **Kottlilil S**, Terrault N, Amara D, Husson J, Huprikar S, Florman S, Sulkowski MS, Durand CM, Luetkemeyer AF, Rogers R, Grab J, Haydel B, Blumberg E, Dove L, Emond J, Olthoff K, Smith C, Fishbein T, Masur H, Stock PG. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant. *Am J Transplant*. 2020 Dec 4. doi: 10.1111/ajt.16427.
255. Khanam A and **Kottlilil S**. Abnormal innate immunity in acute-on chronic liver failure: immunotargets for therapeutics. *Front Immunol* (2020) 11: 2013.
256. Khanam A, **Kottlilil S**, and Wilson E. Reconstitution of T follicular helper-humoral immune axis with elimination of hepatitis C. *Sci Rep* (2020) (1):19924
257. Orr C, Xu W, Masur H, **Kottlilil S** and Meissner EG. Gene Signature predicts relapse to DAA therapy in HCV patients *BMC Infect Dis* (2020), 20: 929.
258. Khanam A, **Kottlilil S**. Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management. *Front Med* (Lausanne). 2021 Nov 8;8:752875.
259. Malave Sanchez M, Saleeb P, **Kottlilil S**, Mathur P. Oral Polio Vaccine to Protect Against COVID-19: Out of the Box Strategies? *Open Forum Infect Dis*. 2021 Jul 9;8(8):ofab367.
260. Khanam A, Saleeb PG, **Kottlilil S**. Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured? 2021 *Cells*. May 4;10(5):1097
261. Khanam A, Chua JV, **Kottlilil S**. Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression. *Int J Mol Sci*. 2021 May 23;22(11):5497.
262. O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Hou P, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. *N Engl J Med*. 2021 Sep 23;385(13):1184-1195.
263. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C, Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Roque-Guerrero L, Acloque G, Aazami H, Cannon K, Simón-Campos JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. *N Engl J Med*. 2021 Dec 2;385(23):e81.
264. Shrivastava S, **Kottlilil S**, Sherman KE, Masur H, Tang L. CCR5+ T-Cells Homed to the Liver Exhibit Inflammatory and Profibrogenic Signatures in Chronic HIV/HCV-Coinfected Patients. *Viruses*. 2021 Oct 14;13(10):2074.

265. Chumakov K, Avidan MS, Benn CS, Bertozzi SM, Blatt L, Chang AY, Jamison DT, Khader SA, **Kottilil S**, Netea MG, Sparrow A, Gallo RC. Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. *Proc Natl Acad Sci U S A*. 2021 May 25;118(21):e2101718118.
266. Doub JB, Ng VY, Johnson A, Amoroso A, **Kottilil S**, Wilson E. Potential Use of Adjuvant Bacteriophage Therapy With Debridement, Antibiotics, and Implant Retention Surgery to Treat Chronic Prosthetic Joint Infections. *Open Forum Infect Dis*. 2021 May 26;8(6):ofab277.
267. Habibzadeh F, Sajadi MM, Chumakov K, Yadollahie M, **Kottilil S**, Simi A, Stafford K, Saeidimehr S, Rafiei M, Gallo RC. COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine. *JAMA Net Open*. 2021 Nov 1;4(11):e2135044.
268. Ayithan N, Tang L, Tan SK, Chen D, Wallin JJ, Fletcher SP, **Kottilil S**, Poonia B. Follicular Helper T (T_{FH}) Cell Targeting by TLR8 Signaling For Improving HBsAg-Specific B Cell Response In Chronic Hepatitis B Patients. *Front Immunol*. 2021 Aug 26;12:735913.
269. **Kottilil S** Reviews of " Efficacy of the Measles-Mumps-Rubella(MMR) Vaccine in the Reducing the Severity of COVID-19: An Interim Analysis of a Randomized Controlled Clinical Trial " *Rapid Reviews: COVID-19*, 2021, DOI: <https://doi.org/10.1162/2e3983f5.8f2bc3be>
270. Ayithan N, Ghosh A, Dwivedi A, Wallin JJ, Tan SK, Chen D, **Kottilil S**, and Poonia B. Oral TLR-8 agonist Selgantolimod induces multiple immune cell responses in humans. 2021, *Viruses* 30: 13:2400.
271. Abutaleb A, Almario JA, Alghsoon S, Yoon JA, Gheysens K, **Kottilil S**, Wilson E. Higher Levels of Fibrosis in a Cohort of Veterans with Chronic Viral Hepatitis are Associated with Extrahepatic Cancers. *J Clin Exp Hepatol*. 2021 Mar-Apr;11(2):195-200.
272. Wellington J, Ma A, **Kottilil S**, Ravichandran B, Husson J, Bruno D, Wilson E. Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis. *Viruses*. 2021 Sep 14;13(9):1831
273. Khanam A, Tang LSY, **Kottilil S**. PD-1 Expressing CD8+CXCR5+ Follicular T Cells Constitute Effector Rather Than Exhaustive Phenotype in Patients with Chronic Hepatitis B. *Hepatology*. 2022, 75: 690-708.
274. Habibzadeh F, Sajadi MM, Chumakov K, Yadollahie M, **Kottilil S**, Simi A, Stafford K, Saeidimehr S, Rafiei M, Gallo RC. Use of Oral Polio Vaccine and the Incidence of COVID-19 in the World. 2021, *PLoS ONE* (in press).
275. Heil E and **Kottilil S**. Is it Goldilocks time for Remdesivir? *N. Engl J Med*. 2021; 386: 385-387.
276. Ball LE, Agana B, Comte-Walters S, Rockey DC, Masur H, **Kottilil S**, Meissner EG. Hepatitis C Virus Treatment with Direct Acting Agents Induces Rapid Changes in Hepatic Proteome. *J Vir Hep* 2021 Nov;28(11):1614-1623
277. Mathur P and **Kottilil S**. Do we need expert HCV treaters or are amateur treaters good enough as we move forward. *Clin Dilemma in Viral Liver Disease* (2021) 2nd ed. DOI: 10.1002/9781119533481.ch35
278. Brokus C, Kattakuzhy S, Gayle B, Narayanan S, Davis A, Cover A, Eyasu R, Ebah E, Ogbumbadiugha-Weekes O, Hoffmann J, Silk R, Stevens J, Mount J, Gannon C, Nussdorf L, Mathur P, Bijole P, Jones M, Kier R, Sternberg D, Greenblatt A, Weintraub E, Masur H,

- Kottlil S**, Rosenthal E. Suboptimal Uptake, Retention, and Adherence of Daily Oral Pre-exposure Prophylaxis Among People With Opioid Use Disorder Receiving Hepatitis C Virus Treatment. *Open Forum Infect Dis*. 2021 Dec 29;9(3):ofab658.
279. Narayanan S, Chua J and **Kottlil S**. Reviews of "Evidence of Increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals" *Rapid Reviews: COVID-19*, 2021, DOI: <https://doi.org/10.1162/2e3983f5.8439471a>
280. Kottlil S, and **Garcia-Martinez J**. Reviews of "Efficacy of the Measles-Mumps-Rubella(MMR) Vaccine in the Reducing the Severity of COVID-19: An Interim Analysis of a Randomized Controlled Clinical Trial" *Rapid Reviews: COVID-19*, 2021, DOI: 10.1162/2e3983f5.40ddd50
281. Reingold A, Chumakov K, Narayanan S, Chua J and **Kottlil S**. Reviews of "Evidence of Increased breakthrough rates of SARS-CoV-2 variants" *Rapid Reviews: COVID-19*, 2021, DOI: <https://doi.org/10.1162/2e3983f5.c44f160c>
282. Welker J, Pulido J, Catanzaro A, Malvestutto C, Li Z, Cohen J, Whitman E, Byrne D, Giddings O, Lake J, Chua JV, Li E, Chen J, Zhou X, He K, Gates D, Kaur A, Chen J, Chou H-Y, Davenport M, Touomou R, Liu Y, Zheng P, **Kottlil S**. A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Therapeutic Efficacy and Safety of CD24Fc in Hospitalised Patients with COVID-19. *Lancet Infect Dis* 2021. (in press).
283. O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan K-C, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM, COVID-19 Phase 3 Prevention Trial Team. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial, *JAMA*, 2022 Jan 14. doi: 10.1001/jama.2021.24939.
284. AY, Peter Aaby, Benn CS, Bertozzi SM, Blatt L, Chumakov K, Khader SA, **Kottlil S**, Nekkar M, Netea MG, Sparrow A, Jamison DJ. One vaccine to counter many diseases? Modelling the economics of oral polio vaccine against child mortality and COVID-19. *PLOS Global Public Health* 2022 (in press).
285. Nelson AK, Fiskum G, Renn C, Zhu S, **Kottlil S**, Klinedinst NJ. Mechanisms of Musculoskeletal Frailty in People Living with HIV. *J Frailty Aging*. 2022;11(1):83-90.
286. Gener AR, **Kottlil S**. Toward demystifying HIV as a risk factor for coronavirus disease 2019 complications. *AIDS*. 2022 Apr 1;36(5):749-750.
287. Ahodantin J, Nio K, Funaki M, Zhai X, Wilson E, **Kottlil S**, Cheng L, Li G, Su L. Type I interferons and TGF- β cooperate to induce liver fibrosis during HIV-1 infection under antiretroviral therapy. *JCI Insight*. 2022 May 31:e152738.
288. Abutaleb A and **Kottlil S**. Review of COVID-19 Associated Hepatitis in children (CAH-C) during the second wave of SARS-CoV-2 infections in Central India: Is it a complication or transient phenomenon. *Rapid Reviews: COVID-19*, 2022 (in press)
289. Ryan MC, Wilson E, **Kottlil S**, Ernst T, Chang L. Quantifying Neuropsychiatric Symptoms in Post-Acute Sequelae of COVID-19 using NIH Toolbox® and PROMIS, 2023, *Neuroimmune Pharmacotherapy* 2(2):95-101

290. Liang H, Ernst T, Oishi K, Ryan MC, Cunningham C, Wilson E, Levine A, **Kottilil S**, Chang L. Abnormal Brain Diffusivity in Participants with Persistent Neuropsychiatric Symptoms after COVID-19. 2023 *Neuro Immune Pharmacotherapy* 2(1):37-48
291. Saleh MG, Chang L, Liang H, Ryan MC, Cunningham E, Garner J, Wilson E, Levine AR, **Kottilil S**, Ernst T. Brain glutathione and γ -aminobutyric acid in individuals with post-acute sequelae of COVID-19. *Annals of Neurology* 2022, 2(2):89-94.
292. Khanam A, Ghosh A, Chua J, and **Kottilil S**. Blockade of CCR4 Breaks Immune Tolerance in Chronic Hepatitis B Patients by Modulating Regulatory Pathways and Enhancing Antiviral Immune Response *J Trans Med* 2023, 21(1):271
293. Mathur P, Ghosh A. and **Kottilil S**. Persistent CD38 expression on CD8 T lymphocytes contributes to altered mitochondrial function and chronic inflammation in people with HIV, despite ART *J. AIDS* 2022, 91:410-422.
294. Mathur P, **Kottilil S**, and Wilson E. Case Report and Review of Management of HIV/HCV Coinfection After Treatment Failure. *Current Treat Options Infect Dis* 2022 DOI 10.1007/s40506-022-00259-y
295. Price AS, Nelson AK, Ghosh A, Poonia B, **Kottilil S**. and Chua JV. A Phase 2 Open Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects with Hepatitis B Virus Infection. *J Med Virol.* 2022,
296. Mathur P. and **Kottilil S**. Immunomodulators for COVID-19. *Front Immunol.* 2022 (in press)
297. Belliveau O, Sahagun SJ McLaughlin M, Curl K-C, Dee N, Masur H, Kottilil S, and Hadigan C. Progression of liver disease in the post-direct acting antiviral (DAA) era of HCV therapy among those with and without HIV. *Antiviral Therapy* 2022 (in press)
298. D'Amore A, Sirajuddin A, **Kottilil S**, Ahlman M, Masur H, George N, and Mathur P. Cardiac Magnetic Resonance Imaging as a Modality for Cardiovascular Disease Risk Evaluation in Patients with Hepatitis C: Data from the CHROME Study. *Open Infect Dis Forum* 2022, (in press)
299. Sanchez-Malave M, Narayanan and **Kottilil S**. Impact of Opioid Use Disorder in Infectious Diseases Practice *Clini Infect Dis* 2022 (in press)
300. Chang AY, Aaby P, Avidan MS, Benn C, Bertozzi SM, Blatt L, Chumakov K, Khader S, **Kottilil S**, Nekkar M, Netea M, Sparrow A, Jameson D. One vaccine to counter many diseases? Modelling the economics of oral polio vaccine against child mortality and COVID-19, 2022 *Front Public Health* (in press)
301. Musabaev E, Estes C, Sadirova S, Bakieva S, Brigida K, Dunn R, **Kottilil S**, Mathur P, Abutaleb A, Razavi-Shearer K, Anstiss T, Yusupaliev B, Razavi H Viral hepatitis elimination challenges in low- and middle-income countries - Uzbekistan Hepatitis Elimination Program (UHEP). *Liver Int.* 2023 doi: 10.1111/liv.15514.
302. Price AS, Nelson AK, Ghosh A, **Kottilil S**, Chua JV. A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection. *J Med Virol.* 2023 95(1):e28105
303. Tu SS, **Kottilil S**, Mattingly JT. Leveraging old Hepatitis C therapies 2024, *New Engl J Med.* doi: 10.1056/NEJMp2409842.
304. Khanam A and **Kottilil S**. Reversal of immune exhaustion for functional cure of chronic hepatitis B: Is the time right? 2024, *Hepatology*, (in press)

305. AlBukhari M, Bagies M, Lizbeth T, and **Kottlilil S**. Fighting fire with fire: Novel Therapeutic Approaches for Infectious Diseases. *Future Microbiology*, 2024, 19:1177-1184.
306. Yen DW, Barin B, Rouster SD, Terrault NA, Price JC, Shata MT, Blackard JT, **Kottlilil S** and Sherman KE. Prevalence of Hepatitis E infection in HIV Negative and Positive Transplant Recipients. *Clin Infect Dis*. 2024 (in press)
307. The Polaris Observatory collaborators. Number of people living with hepatitis C virus treated in 2014-2023 and key learning that can apply to new therapies for HBV, HDV, and MASLD/MASH. *J. Hepatology*. 2024 (in press)
308. Mollenkopf S, Rosenthal E, Teferi G, Silk R, George N, Masur H, **Kottlilil S**, Kattakuzhy S. Sustained Impact of Task-Shifting HCV Treatment to Non-Specialist Providers: Five Year Follow Up of the ASCEND Investigation. *Annals Intern Med* 2024, (in press)
309. Khanam A, **Kottlilil S**. and Tang L. Selgantolimod whole blood stimulation by TruCulture induces innate and adaptive antiviral immune response in chronic hepatitis B. *J Vir Hep*, 2024, in press
310. Khanam A, Mathur P, Abutaleb A, Yurdaydin C, **Kottlilil S**. Hepatitis Delta virus: The smallest, yet the precarious one. *Gastroenterology*, 2024 (in press).
311. Khanam A, Abutaleb A, Ghosh A, Kaysin F, Zeybel M, Yurdaydin C. and Kottlilil S. Immune clearance of HDV in chronically infected individuals. *J. Clin Inv*. 2024 (2024).
312. Mathur P, Khanam A, and **Kottlilil S**. Hepatitis Delta: A Narrative Review. *Microorganisms*. 2024, 12:2177
313. Bradford W, Akselrod H, Bassler J, Gagnon KW, Burkholder G, Carpenter JE, Steck A, Catalanotti J, Kuo I, McGonigle K, Mai W, Notis M, Brokus C, Kattakuzhy S, Rosenthal E, Eaton EF. Hospitalization is a missed opportunity for HIV screening, pre-exposure prophylaxis, and treatment. *Addict Sci Clin Pract*. 2024;19(1):22.
314. Schmalzle SA, Maroosis D, Masur H, **Kottlilil S**, Mathur P. Use of a machine learning model to predict retention in care in an urban HIV clinic. *AIDS*. 2024;38(1):125-127.
315. Mathur P, **Kottlilil S**. Novel oral polio vaccine for serotype 2: new hope. *Lancet Infect Dis*. 2024 (3):223-224.
316. Sneller L, Lin C, Price A, **Kottlilil S**, Chua JV. RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects. *Microorganisms*. 2024;12(3):599
317. Buanec HL, Schiavon V, Merandet M, How-Kit A, Bergerat D, Fombellida-Lopez C, Bensussan A, Bouaziz JD, Burny A, Darcis G, Song H, Sajadi MM, **Kottlilil S**, Gallo RC, Zagury D. Early elevated IFN α is a key mediator of HIV pathogenesis. *Commun Med (Lond)*. 2024;4(1):53.
318. Le Buanec H, Schiavon V, Merandet M, How-Kit A, Song H, Bergerat D, Fombellida-Lopez C, Bensussan A, Bouaziz JD, Burny A, Darcis G, Sajadi MM, **Kottlilil S**, Zagury D, Gallo RC IFN α induces CCR5 in CD4⁺ T cells of HIV patients causing pathogenic elevation. *Commun Med (Lond)*. 2024;4(1):52.
319. Ghosh A, Khanam A, Ray K, Mathur P, Subramanian A, Poonia B, **Kottlilil S** CD38: an ecto-enzyme with functional diversity in T cells. *Front Immunol*. 2023;14:1146791.
320. Gane EJ, Dunbar PR, Brooks AE, Zhang F, Chen D, Wallin JJ, van Buuren N, Arora P, Fletcher SP, Tan SK, Yang JC, Gaggari A, **Kottlilil S**, Tang L. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression. *J Hepatol*. 2023;78(3):513-523.

321. Rosenthal ES, Brokus C, Sun J, Carpenter JE, Catalanotti J, Eaton EF, Steck AR, Kuo I, Burkholder GA, Akselrod H, McGonigle K, Moran T, Mai W, Notis M, Del Rio C, Greenberg A, Saag MS, **Kottlilil S**, Masur H, Kattakuzhy S. Undertreatment of opioid use disorder in patients hospitalized with injection drug use-associated infections. *AIDS*. 2023;37(12):1799-1809.
322. O'Brien TR, Lee MH, Wilson E, **Kottlilil S**. *IFNL4* Genotype Frequencies in Asian Populations Support Shorter Duration Therapy with Sofosbuvir-Based Hepatitis C Virus Regimens to Increase the Number Cured. *J Interferon Cytokine Res*. 2023;43(9):435-438
323. Narayanan S, Ching PR, Traver EC, George N, Amoroso A, **Kottlilil S**. Predictors of Nonadherence Among Patients With Infectious Complications of Substance Use Who Are Discharged on Parenteral Antimicrobial Therapy. *Open Forum Infect Dis*. 2022 Dec 13;10(1):ofac633.
324. Carpenter JE, Catalanotti J, Notis M, Brokus C, Moran TP, Akselrod H, Burkholder G, Eaton EF, Kuo I, Mai W, McGonigle K, Steck A, Del Rio C, Saag M, **Kottlilil S**, Masur H, Kattakuzhy S, Rosenthal ES. Use of nonstigmatizing language is associated with improved outcomes in hospitalized people who inject drugs. *J Hosp Med*. 2023;18(8):670-676.
325. Islam M, Kumar K, Sevak JK, Jindal A, Vyas AK, Ramakrishna G, **Kottlilil S**, Sharma MK, Sarin SK, Trehanpati N. Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN. *Hepatology*. 2023;77(5):e0098.
326. APASL Expert Panel. Acute on chronic liver failure: the Kyoto Consensus-Steps from Asia. *Hepatology International* 2025, 1: 1-69.
327. Harfouch O, Whitfield D, Mammadli T, Eyasu R, Volpi C, Mansfield M, Omari H, Ebah E, Davis A, Zoltick M, Cover A, Bijole P, Silk R, Sternberg D, Liu T, Garrett G, Jones M, Kier R, Masur H, **Kottlilil S**, Kattakuzhy S, and Rosenthal E. A sequential mixed model methods study of factors associated with low High-resolution anoscopy completion in transgender women with abnormal anal cytology. *AIDS Pat Care STDs*, 2025, 39: 36-43
328. Li G, Lou, Y, Ma J, Cheng, L, Yu H, Tshouridis O, He X, Funaki M, Ahodantin J, Bi W, Chen J, Fan X, Sharaf S, Goonetilleke N, Jones BR, Kottlilil S, Mathur P, and Su L. Depletion of pDCs rescues HIV-reactive stem-like CD8 T cells during chronic HIV-1 infection. *Sci Trans Med* (2025) 17: 823.
329. Tu SS, Kottlilil S, Mattingly J Jr. Leveraging Old Hepatitis C Therapies. 2024 *New Engl J Med*. doi: 10.1056/NEJMp2409842
330. Choudhury A, Kulkarni AV, Arora V, Sooin AS, Dokmeci AK, Chowdhury A, Koshy A, Duseja A, Kumar A, Mishra AK, Patwa AK, Sood A, Roy A, Shukla A, Chan A, Krag A, Mukund A, Mandot A, Goel A, Butt AS, Sahney A, Shrestha A, Cárdenas A, Di Giorgio A, Arora A, Anand AC, Dhawan A, Jindal A, Saraya A, Srivastava A, Kumar A, Kaewdech A, Pande A, Rastogi A, Valsan A, Goel A, Kumar A, Singal AK, Tanaka A, Coilly A, Singh A, Meena BL, Jagadisan B, Sharma BC, Lal BB, Eapen CE, Yaghi C, Kedarisetty CK, Kim CW, Panackel C, Yu C, Kalal CR, Bihari C, Huang CH, Vasishtha C, Jansen C, Strassburg C, Lin CY, Karvellas CJ, **Kottlilil S**. Lesmana CRA, Philips CA, Shawcross D, Kapoor D, Agrawal D, Payawal DA, Praharaj DL, Jothimani D, Song DS, Kim DJ, Kim DS, Zhongping D, Karim F, Durand F, Shiha GE, D'Amico G, Lau GK, Pati GK, Narro GEC, Lee GH, Adali G, Dhakal GP, Szabo G, Lin HC, Li H, Nair HK, Devarbhavi H, Tevethia H, Ghazinian H, Ilango H, Yu HL, Hasan I, Fernandez J, George J, Behari J, Fung J, Bajaj J, Benjamin J, Lai JC, Jia J, Hu JH, Chen JJ, Hou JL, Yang JM, Chang J, Trebicka

- J, Kalf JC, Sollano JD, Varghese J, Arab JP, Li J, Reddy KR, Raja K, Panda K, Kajal K, Kumar K, Madan K, Kalista KF, Thanapirom K, Win K et al. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia. *Hepatology*. 2025 Feb;19(1):1-69. doi: 10.1007/s12072-024-10773-4. Epub 2025 Feb 17. PMID: 39961976
331. Mathur P, Khanam A, **Kottilil S**. Microorganisms. Chronic Hepatitis D Virus Infection and Its Treatment: A Narrative Review. 2024 Oct 29;12(11):2177. doi: 10.3390/microorganisms12112177. PMID: 39597566
332. Polaris Observatory Collaborators. Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies. *J Hepatol*. 2025 Aug;83(2):329-347. doi: 10.1016/j.jhep.2025.01.013. Epub 2025 Feb 4. PMID: 39914746
333. Sneller L, Mathur K, **Kottilil S**, Mathur P. Hot and Cold HCC: Uncoupling Viral Oncogenesis and Therapy. *Viruses*. 2025 Sep 17;17(9):1255. doi: 10.3390/v17091255. PMID: 41012682
334. Khanam A, Ameer A, Mathur P, Yurdaydin C, **Kottilil S**. Host Immune Response in Chronic Hepatitis Delta: Implications for Pathogenesis and Therapy. *Pathogens*. 2025 Aug 21;14(8):828. doi: 10.3390/pathogens14080828. PMID: 40872338
335. Liu P, Ernst T, Liang H, Jiang D, Cunningham E, Ryan M, Lu H, **Kottilil S**, Chang L. Elevated cerebral oxygen extraction in patients with post-COVID conditions. *NeuroImmune Pharm Ther*. 2024 Nov 20;3(3-4):169-174. doi: 10.1515/nipt-2024-0014. eCollection 2024 Sep. PMID: 39959306
336. Khanam A, **Kottilil S**. Reversal of immune exhaustion for functional cure of chronic hepatitis B: Is the time right? *Hepatology*. 2025 Apr 1;81(4):1129-1131. doi: 10.1097/HEP.0000000000001059. Epub 2024 Aug 13. PMID: 39141593
337. Harfouch O, Lisco A, Omari H, Eyasu R, Davis A, Zoltick M, Ebah E, Cover A, Bijole P, Silk R, Sternberg D, Liu T, Garrett G, Jones M, Kier R, Masur H, **Kottilil S**, Kattakuzhy S, Rosenthal ES. High Rates of High-risk HPV Anal Infection and Abnormal Cytology in a Cohort of Transgender People Assigned Male at Birth. *Open Forum Infect Dis*. 2024 Nov 12;11(12):ofae662. doi: 10.1093/ofid/ofae662. eCollection 2024 Dec. PMID: 39679352
338. Mollenkopf S, Rosenthal E, Teferi G, Silk R, George N, Masur H, **Kottilil S**, Kattakuzhy S. Sustained Impact of Task-shifting HCV Treatment to Nonspecialist Providers: 5-Year Follow Up of the ASCEND Investigation. *Open Forum Infect Dis*. 2025 Mar 22;12(4):ofaf174. doi: 10.1093/ofid/ofaf174. eCollection 2025 Apr. PMID: 40256044
339. Harfouch O, Whitfield D, Mammadli T, Eyasu R, Volpi C, Mansfield M, Omari H, Ebah E, Davis A, Zoltick M, Cover A, Bijole P, Silk R, Sternberg D, Liu T, Garrett G, Jones M, Kier R, Masur H, **Kottilil S**, Kattakuzhy S, Rosenthal ES. A Sequential Mixed-Methods Study of Factors Associated with Low High-Resolution Anoscopy Completion in Transgender Women with Abnormal Anal Cytology. *AIDS Patient Care STDS*. 2025 Feb;39(2):36-43. doi: 10.1089/apc.2024.0244. Epub 2025 Jan 27. PMID: 39866129
340. Wang VL, Derenoncourt M, Brokus C, Stevens J, Carpenter J, Steck A, Kuo I, Catalanotti JS, Akselrod H, Burgan K, Burkholder G, Eaton E, Masur H, **Kottilil S**, Rosenthal E, Kattakuzhy S. Major barriers and facilitators of care for patients with infectious complications of opioid use disorder: A multi-site, qualitative analysis of expert stakeholders from the CHOICE protocol. *J Subst Use Addict Treat*. 2025 Nov;178:209778. doi: 10.1016/j.josat.2025.209778. Epub 2025 Aug 8. PMID: 40784407
341. Gane E, Chen M, Lawitz E, Jacobson I, Chua J, **Kottilil S**, Lau A, Xu S, Kwo P, Yuen MF, Yang C, and Cheng G. A First-in-Human Study of AHB-137, an Unconjugated Antisense

- Oligonucleotide, in Healthy Subjects and Patients with Chronic Hepatitis B. *Hepatology* 2026 (in press).
342. Sneller L, Mathur K, **Kottilil S**, and Mathur P. Hot and Cold HCC: Uncoupling viral oncogenesis and therapy. *Viruses* (2025), 17: 1255.
 343. D'Amore A, Sirajuddin A, George N, Ajlman M, Matta J, Masur H, **Kottilil S** and Mathur P, Cardiac MRI Identifies Subclinical Myocardial Tissue Abnormalities in Individuals with Hepatitis C Regardless of Myocardial Damage Markers or Fibrosis Stage. *J Vir Hepatitis* (2026) in press.
 344. Ahodantin J, Wu J, Funaki M, Tang L, **Kottilil S**, and Su L. HEPLISAV-B breaks immune tolerance and induces HBV control via CD4 T cell-dependent mechanisms in a chronic hepatitis B mouse model. *bioRxiv* (2026), doi: 10.64898/2026.03.13.711721.
 345. **Kottilil S**. Da Silva Jardine, Mitchnick M, Smith R, Rechio S, Herce H, Moss RB, Garcia RJ, Sneller L, Mathur P, Crystal C and Torkan B, and Eisenberg P: A first in human phase - 1 study of an intranasal fusion inhibitor for the treatment of COVID-19 infection. *Lancet Microbe* 2026 (in press).
 346. Pranesh G, Ghosh A, Zakhariah N, Murakami E, Mathur P, Heredia A, Nass L-B, Weng S, Ramanathan A, **Kottilil S** and Subramanian M. Pharmacological Profiling of Intravenous MP-04: Sustained NAD⁺ Augmentation, Immune Modulation, and Renal Protection in Preclinical Models, *Frontiers Pharm.* (2026), in press.

Book Chapters

1. Cortez KJ, Jackson JO, and **Kottilil S**. Role of Chemokine and Chemokine receptors in the Pathogenesis of Infectious diseases. *In Current Topics in Membranes* (2005), 55:189.
2. Allison R, and **Kottilil S**. Host Immune Responses in HIV Infection. *In Host Gene Responses to RNA Viral Infection* (2008), 59-82.
3. Sherman AC and **Kottilil S**. HBV Biology: replication, Mutation and Evolution. *In HIV and Liver Disease* (2010), 125-33.
4. Tang L, **Kottilil S**, Meissner EG *Hepatology- Virology and Pathogenesis of Hepatitis C*, in 7th edition of Zakim and Boyer's *Hepatology*. Edited by Norah Terrault (2017)
5. **Kottilil S**, Sherman KE. Hepatitis A and E infection. *In Schiff's Diseases of the Liver.* (2017)
6. Beigel J and **Kottilil S**. Antiviral therapy (non-HIV). *In Cecil's Textbook of Internal Medicine* (2018).
7. El-Kamary S and **Kottilil S**. Viral Hepatitis. *In Hunter's Textbook of Tropical Medicine.* (2018).
8. Deming M and **Kottilil S**. Maternal infections and sexually transmitted diseases in pregnancy. *In Clinical Obstetrics.*
9. Mathur, P, Malave M and **Kottilil S**. Antiviral Therapy in *Principles and Practices of Infectious Diseases* (2023) Ed. Cohen J and Holland SM
10. Tang LSY, Wilson E. and **Kottilil S**. Hepatitis in *Principles and Practices of Infectious Diseases* (2023) Ed. Cohen J and Holland SM
11. Narayanan S. And **Kottilil S**. Miscellaneous Antivirals in Principle and Practices of Infectious Diseases (2023). Ed. Cohn J and Holland SM

Major Invited Speeches:

1. An invited lecture titled “Why T Cell-Mediated Immunity fails in HIV infection? A Gut Response” at Department of Pathology, University of Massachusetts, Worcester, MA on April 16, 1997.
2. An invited lecture at the Kenney Day Celebrations of Brown University School of Medicine at Memorial Hospital of Rhode Island on February 06,1998 on “Role of CTLs in HIV infection”.
3. Brown University School of Medicine lecture series on HIV lecture titled “Effect of Immunotherapy in HIV Infection” on March 11, 1999.
4. Infectious Disease Grand Rounds at San Francisco General Hospital “Neurosyphilis in HIV-infected Individuals” on April 22, 1999.
5. An oral presentation titled “Innate Immune Defense Mechanisms Involved in the Control of HIV Replication: Inverse Correlation of HIV viremia with NK cell Function.” at the 9th Conference on retroviruses and Opportunistic Infections held at Seattle, during Feb 24-28, 2002.
6. An oral presentation titled “Predictive ability of HCV Viral Decay Kinetics in Predicting Treatment Response to Peginterferon Alpha 2b and Ribavirin Among HIV/HCV Co-infected Individuals” at the 2nd IAS meeting on HIV Pathogenesis held at Paris, France during July 13-16, 2003.
7. An oral presentation titled “Virologic, Biochemical and Histologic Response to Peginterferon Alpha 2b and Ribavirin Among HIV/HCV Co-infected Patients” at the 43rd ICAAC meeting held at Chicago, IL during Sept 14-17, 2003.
8. An oral presentation titled “HCV Resistance to Peginterferon/Ribavirin Therapy is associated with Increased Immune Activation in HCV/HIV Co-infected patients” at the 11th Conference on Retroviruses and Opportunistic Infections held at San Francisco, CA during Feb 07-11, 2004.
9. National Institute of Allergy & Immunology Grand Rounds on “ HIV/HCV co-infection and its Impact on HAART and Hepatotoxicity” held on April 30, 2004.
10. National Institutes of Health Clinical Research Center Grand Rounds on “HIV infection, HCV infection, and ART: The Perfect Storm” on September 15, 2004.
11. “Innate immunity in HIV infection: Enhanced NK cell-death and turnover mediated by altered expression of interferon-stimulated genes (ISG)s.” at the 12th Conference on Retrovirus and Opportunistic Infection held at Boston, MA during Feb 22-25, 2005.
12. An oral presentation titled “Differential effect of IFN on Dual (HCV and HIV) Viral Kinetics in Vivo” at the 12th International Workshop on HIV Dynamics held at Cleveland, OHIO during April 22-25, 2005.
13. An oral presentation titled “Early HCV Kinetics Prediction of SVR in HIV/HCV Co-infected Individuals Treated with Pegylated Interferon Alpha 2b and Ribavirin” at the 3rd IAS Conference on HIV Pathogenesis and Treatment, held at Rio De Janeiro, Brazil from July 24-27, 2005.
14. An oral presentation titled “Applied Proteomics in HCV/HIV Co-infection: Differential Expression of Serum Proteins Associated with Response to HCV Therapy in HIV Co-infection” at the 45th ICAAC meeting held at Washington DC from Dec 16-19, 2005.
15. Hepatology and Gastroenterology Grand Rounds titled “Genomics and Proteomics in HCV/HIV Co-infection: Differential Expression of genes and proteins associated with response to HCV Therapy in HIV Co-infection” at the Mount Sinai Hospital School of Medicine Liver conference on Feb 03, 2006.

16. NIAID Grand Rounds at the Clinical Research Center on January 19, 2007 titled “Novel insights into antiviral effects of Interferon-alpha on HCV and HIV”
17. Grand Rounds at the Jaslok Hospital, Mumbai, India titled “Applications of Genomics and Proteomics in the management of Infectious Diseases” on September 26, 2007.
18. Invited Speaker at the US-Japan Co-operative Medical Sciences Program at Portland OR on September 20, 2009.
19. Speaker at First NIH-ILBS Conference on HIV. Hepatitis and Co morbidities” held at New Delhi on March 6-7, 2010.
20. NIAID Grand Rounds Speaker on April 16, 2010 on “HBV Resistance”
21. NIH Clinical Center Grand Rounds on HIV, HCV and Liver; Struggles and Solutions” on January 19, 2011.
22. Plenary lecture on Biomarkers for HCV treatment responses at the second Latin American Symposium on Chronic Hepatitis and Liver disease held at Punta Cana, 2011.
23. Infectious Diseases Grand Rounds at Duke University on December 05, 2011.
24. Symposium Chair: 19th Conference on Retroviruses and Opportunistic infections, March 06, 2012
25. Plenary lecture: HIV and HCV coinfection at HIV Congress 2012, Mumbai, India March 16, 2012
26. Panel discussant: Turning the Tide of HIV Epidemic in the District of Columbia International AIDS Conference Washington DC July 2012.
27. Invited Speaker at HIV and Liver Disease 2012 Conference titled Immunopathogenesis of HCV and HBV in HIV infection at Jackson Hole, WY on September 07, 2012.
28. Invited Faculty speaker at the Sino-American Symposium on Translational Medicine: Liver disease Clinical research and drug induced liver injury at Shanghai, China on September 15, 2012.
29. Hepatitis C and HIV: The Borgia effect. Demystifying Medicine series held at National Institutes of Health, Bethesda campus on January 22, 2013.
30. Hepatitis C treatment update for 2013: Annual Conference of the Institute of Human Virology held at Moscow, Russia on September 12, 2013.
31. Invited Speaker at HCV Symposium: Sofosbuvir for Hepatitis C held at Institute of Liver and biliary Sciences, New Delhi, India to be held on November 15th, 2013.
32. Invited speaker at NIAAA conference on Alcohol and Liver Diseases titled “Mechanisms of Alcohol induced hepatocellular carcinoma” to be held at Hotel Ashok, New Delhi, India between November 16-18, 2013.
33. Plenary Talk on Impact of HCV infection in the USA at the National Conference on Indian Health at Billings, MT March 31, 2014.
34. Grand Rounds at Greenbaum Cancer Center, University of Maryland on “Management of HCC; an Infectious Diseases perspective” on April 4, 2014.
35. Invited talk at HIV and Liver Disease 2014 at Jackson Hole, WY September 2014 titled “Immunological strategies to eradicate HBV infection”
36. Invited Speaker at the Annual Conference of the Institute of Human Virology held at Baltimore, MD during Sept 14-17, 2014 titled “State of the Art of HCV management”
37. District of Columbia CFAR: city-wide Seminar series: Update on Hepatitis C management May 2014.

38. Infectious Diseases Grand Rounds at University of Maryland, Baltimore on December 9, 2014 titled “Management of Hepatitis C infection: The new era of combination Directly acting antiviral agent therapy”
39. Invited Speaker at CROI Symposium 2014: HCV and Beyond: Strategies to Eradicate HBV, The Annual Conference on Retroviruses and Opportunistic Infections, 2014 held at Boston MA.
40. Invited lecture at the Annual American Association of the Study of the Liver Meeting held at Boston on November 9th 2104 titled: Once daily ledipasvir and sofosbuvir for treatment of HIV/HCV coinfecting genotype 1 subjects: Final results of the ERADICATE study.
41. Invited Hematology/Oncology Grand Rounds: Greenebaum Cancer Center lecture at the University of Maryland, on December 18th, 2014 on “Antiviral Strategies to prevent hepatocellular carcinoma”
42. Medical Grand Rounds at KEM Hospital on Management of HCV infection in 2015 on February 6, 2015
43. Gastroenterology Grand Rounds on Control and Eradication of Chronic Hepatitis C Infection on February 6, 2015 at Global Hospitals, Mumbai, India.
44. Medicine Grand Rounds at the Institute of Liver and Biliary Sciences on HCV in 2015 on February 10, 2015
45. Basic Science Grand Rounds at the Institute of Liver and Biliary Sciences on “Current Approaches to Eradicate Chronic HBV Infection on February 9, 2015
46. Greenebaum Cancer Center Population Sciences Lecture on “Implications of City Wide Eradication of HCV; The ASCEND Study” on February 18th, 2015
47. “Adaptive strategies to cure chronic hepatitis B” Invited lecture at NIAID ACTG Hepatitis Transformative Sciences Group (TSG) held on February 27, 2015
48. Invited lecture at the IAS-USA Improving the management of HIV Disease Course on “HIV/HCV Coinfection: New Drugs and Drug-Drug Interactions” on May 13, 2015.
49. Invited lecture on “Strategies to eradicate HBV infection” at Digestive Diseases Week, to be held at Washington DC, May 2015
50. Invited lecture at the Asia Pacific Study of Liver Single topic Conference at New Delhi on December 16, 2015 titled “ Management of Hepatitis C infection”
51. Invited Lecture at ID week Novel Drugs in Development to Control or Eradicate Hepatitis B infection on October 8th, 2015.
52. Invited lecture at the 16th International Workshop on The Pharmacology of HIV and Hepatitis on “HBV Therapy: What is in the Pipeline? On May 26, 2015.
53. Medicine Grand Rounds at University of Maryland School of Medicine on October 07, 2015 Hepatitis C update
54. Invited lecture at the Seventh Annual Global Virus Network Meeting at Beijing, China on May 17, 2015 on hepatitis C treatment advances in 2015.
55. Invited lecture on “hepatitis virus” at Short course of Global Virus Network, held at Baltimore on July 10, 2015
56. Invited lecture at HEDART meeting held between December 06-10, 2015 at Maui, HI on “Ultra short courses for HCV therapy”
57. Expert Panel Participant on the future of HCV therapy at national Summit held at Washington DC on June 4th, 2015
58. Plenary lecture on “Evolution of resistance in HCV infection” at APASL Single Topic Conference on December 17, 2015

59. Post graduate Course lecture on “Management of lecture on evolution of resistance in HCV infection at APASL Single Topic Conference on December 18, 2015
60. Plenary lecture on “Management of HCV genotype 3 infection” at APASL Single Topic Conference on December 18, 2015
61. University of Maryland School of Medicine Grand Rounds on HCV management: accomplishments and Challenges” on March 12, 2016
62. Invited lecture at the 2016 Spring Symposium of Greater Washington Infectious Diseases Society on “Strategies to Eradicate HBV infection” held on March 9, 2016
63. Invited lecture at the 17th International Workshop on The Pharmacology of HIV and Hepatitis on “HBV Therapy: What is in the Pipeline? On May 26, 2015.
64. National Institutes of Health Clinical Research Center Grand Rounds on Current Trends of HCV management: Strategy to Global Elimination of HCV” on June 22, 2016.
65. Invited Medicine Grand Rounds on “Management of Hepatitis C for the Internist” on August 19, 2016 at the Harbor East Medstar Hospital, Baltimore, MD
66. Invited lecture on Prevention of hepatocellular Carcinoma using Functional cure of HBV infection” to Tumor Immunology Group, University of Maryland, Baltimore, MD
67. An Invited Plenary lecture on “ HCV Therapy: Accomplishments and Challenges” on the World Hepatitis Day Celebration at Rwanda Ministry of Health Workshop in Kigali, Rwanda on July 28, 2016.
68. An Invited lecture titled “HCV management 2016” at the Annual Meeting of the Global Virus Network in Sapporo, Japan on October 25th, 2016.
69. An invited lecture on “the role of immune check point inhibitor therapy for HIV, HCV and HBV infections’ at Jackson Hole, WY on September 17, 2016
70. An invited lecture on “Functional cure for HBV infection” at the Annual Meeting of the Institute of Human virology at Baltimore on September 22nd, 2016.
71. An invited Plenary lecture on HCV management challenges at the 2nd Annual Conference on Liver diseases at Kolkata, India on December 1st, 2016.
72. Research talk on final results of the ASTRAL-5 study at the 17th Annual Meeting of the Asia Pacific Association on the Study of the Liver: held at Shanghai on February 18th, 2017
73. Medical Grand Rounds at Emory University on March 16th titled “ rationale for ultra short course therapy for HCV” at Atlanta
74. An invited special lecture on “HCV-driven Cancers” during the conference on infectious agents and cancers at Naples, Italy on March 23rd, 2017
75. An invited symposium on “ Hepatitis E: When Why and Where?’ at Digestive Diseases week to be held at Chicago on May 6th, 2017
76. An invited talk on “Research Matters in Cancer Symposium” held at Johns Hopkins University on April 12, 2017.
77. An invited talk on “Current Management of hepatitis C” held at King’s college, London on May 23rd, 2017
78. Chair, Session on “Cardiovascular and Liver Complications associated with HIV infection” October 26, 2017 at the Annual IHV Meeting held in Baltimore, MD
79. An invited talk on “Hepatitis C management in 2017” at the Global Virus Network Annual Meeting in Melbourne, Australia on September 24, 2017.
80. An invited talk on “Hepatitis Viruses” held at the Global virus Network Short course, held on August 14th, 2017.

81. An invited talk at the HEPDART 2017 meeting held at Kona, HI on “Short duration Therapy for Hepatitis C” on December 3, 2017.
82. An invited talk on “Immune based strategies to achieve a functional cure for hepatitis B infection” held at University of Maryland Greenebaum Cancer Center Tumor immunology immunotherapy Retreat held on August 4th, 2017.
83. An invited talk on “Opportunities and Challenges to escalate hepatitis C treatment” update” on World Hepatitis Day Meeting in Kigali, Rwanda on July 28th, 2017.
84. Plenary talk at the 64th Annual AUA meeting titled “Beginning of the end of hepatitis C in 2017” held at Washington DC on May 04, 2017
85. Medical Grand rounds on Management of hepatitis C at the MedStar Harbor East Hospital on September 1, 2017
86. Neuro-infectious Disease Interest Group Grand Rounds on January 17, 2018 at National institute of Mental Health (NIMH) Bethesda campus on “Neurological complications of hepatitis C” NIH, Bethesda MD
87. APAMSA (Asia Pacific American Medical Student Association) Annual Meeting Lunch Seminar on January 20th held at Johns Hopkins Hospital, Baltimore MD.
88. HCV Symposium Talk at Asia Pacific Association of Liver Diseases 2018 Annual Meeting titled “Bridging Gaps in HCV care cascade: task shifting” at New Delhi, India
89. Plenary Talk at Asia Pacific Association of Liver Diseases 2018 Annual Meeting titled “Antiviral and immune mediated therapy for chronic hepatitis B” at New Delhi, India.
90. Invited Speaker at the Cancer Prevention and Control/Viral Oncology Seminar Series titled “Treatment of viral hepatitis: A preventive strategy for liver cancer” at Johns Hopkins Hospital on May 1st, 2018.
91. An invited talk on “Research Matters in Cancer Joint Symposium with JHU and UMD” held at University of Maryland on June 7, 2018.
92. An invited faculty seminar at University of Puerto Rico PRINBRE at Turabo on March 5th 2018 titled “Immune recovery for chronic viral infections; Lessons learned from HCV”
93. An invited faculty seminar at University of Puerto Rico PRINBRE at San Juan on March 6th 2018 titled “Strategies to cure HBV infection”
94. Seminar at university of Miami CFAR titled’ Management of Hepatitis C in 2018: Accomplishments and Challenges” on Feb 08, 2018.
95. An invited talk at American College of Physicians DC Chapter meeting to be held in October 2018 titled “Impact of HIV infection on cardiovascular effects of HIV infection”
96. An invited talk at the Annual CIHEB Research Strategic Meeting titled “From protocol to publication” on May 24, 2018
97. An invited talk on “Hepatitis Viruses” held at the Global virus Network Short course, held on August 14th, 2018.
98. Medical Grand Rounds on Management of hepatitis C at the MedStar Harbor East Hospital on August 3rd, 2018
99. ACTG Think Tank Annual Symposium titled” Immune strategies to eliminate chronic hepatitis B’ held on June 22, 2018 in Washington DC
100. An invited lecture on “CCR2 and CCR5 antagonism in liver disease” at HIV and Liver Disease meeting held at Jackson Hole, WY on September 14, 2018
101. Invited lecture at the Annual ACCP Meeting Symposium held at Chicago, IL on The Opioid Crisis: The Accompanying Increase in Infectious Diseases &How the Crisis Can Be Mitigated on September 17th, 2019

102. An invited lecture on “Advances in Hepatitis B therapeutics” at the Hot Spots Meeting at Hyderabad, India on January 4th 2020
103. An invited lecture on “Hot Topics in 2020” at the Hot Spots Meeting at Hyderabad, India on January 5th 2020
104. GWAPI webinar on COVID-19: Current topics and Future Therapeutics” held on May 30, 2020
105. Plenary lecture titled “Pharmacologic Treatment of COVID-19” at Annual Meeting of the Maryland Academy of Advanced Practice Clinicians held on October 3rd. 2020.
106. Grand Rounds at Family Medicine at University of Maryland on “CoVID-19 Therapeutics” held on May 27, 2020
107. Oration in honor of Dr. D. M. Vasudevan at Jubilee Mission Hospital on March 7th, 2020 titled “ A tribute to the Master: One student, one disease”
108. World Hepatitis Day Seminar titled “Novel Molecules and Integrated Care for Hepatitis B in the COVID-19 era” on July 28, 2020
109. “COVID-19 update” Invited lecture to Kerala Health Sciences University on September 19, 2022
110. An invited NIDA symposium lecture on Cannabinoids and COVID-19 at ASAM meeting in 2021.
111. An invited lecture on Viral infections in Substance use disorders” at Annual ISAM meeting held at Malta in 2022.
112. John C Martin Oration on history of hepatitis therapeutic development at Kolkata Liver Meeting, to be held on December 16, 2022.
113. National Institutes of Health NIAID Grand Rounds on Hepatitis B infection in 2023
114. An invited lecture on Approaches to Hepatitis B Functional cure at Jackson Hole, WY in 2023
115. An invited lecture on mechanism based clinical trial development at Kolkata, India in April 2024
116. National Institutes of Health Clinical Center Grand Rounds on Hepatitis Delta immunology in 2024
117. Global Virus Network Short Course lecture on Hepatitis B on July 15, 2024
118. Invited speaker at Annual Achieve Conference at Halifax, Nova Scotia, Canada during September 20-22, 2024
119. Invited lecture titled “Scientific rationale for functional cure of hepatitis B infection” at 9th Kolkata Liver Meeting held at Kolkata, India during December 12-14, 2024
120. Special lecture at NIAID Laboratory of Immunoregulation and Infectious Diseases (LIRID) on “Functional Cure for Hepatitis B” March 17th, 2025
121. National Institutes of Health Clinical Center Grand Rounds on “Hepatitis Delta Virus” on May 21, 2025
122. An invited lecture on “Immune and non-immune based therapies for hepatitis B Combination therapy over monotherapy” at Jackson Hole, WY in 2023
123. An invited lecture at the National Academy of Medical Sciences Annual Meeting held at Jodhpur, India on November 23rd, 2024
124. An invited lecture on “Sepsis associated with ACLF” at AASLD Hot Spots Meeting held at New Delhi on March 2, 2025
125. An invited lecture on “Approaches to cure hepatitis B” at AASLD Hot Spots Meeting held at New Delhi on March 3, 2025

126. An invited lecture on “My favorite paper at AASLD” at AASLD Hot Spots Meeting held at New Delhi on March 3, 2025